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ABSTRACT 
Caveolae are small invaginations on the plasma membrane of a variety of 
tissue types and are formed by the caveolin (1 and 2) and cavin (1-3) proteins 
families. Physiological roles implicated for caveolae include vesicular trafficking, 
signal transduction, cell adhesion, and mechanosensation. Over 20 years ago, 
caveolin-1, a small integral membrane protein, was observed to be the major 
tyrosine phosphorylation target in cells transformed by the Src oncogene. 
Subsequently its expression has been widely studied in a variety of cancers 
where it has been shown, confusingly, to have both oncogenic and tumor 
suppressive capabilities in vitro and in vivo. However, the role of cavin family of 
proteins in caveolae has been only recently described and minimally studied in 
this context. Thus to understand possible roles of caveolae in cancer biology, I 
investigated the roles of caveolin-1and cavin-1 in breast cancer cell line behavior 
in vitro. Caveolin-1, and cavin-1 and -2 are expressed to a significant degree in 
aggressive estrogen receptor (ER) negative cell lines but not in ER positive cell 
lines. Forced ER expression, however, does not abrogate the expression of 
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caveolar proteins. Knock-down of caveolin-1and/ or cavin-1 in the ER negative 
cell lines results in increased proliferation, migration, matrigel invasion, and 
matrix metalloproteinase activity. Consistent with this result, a highly metastatic 
variant of one of these cell lines shows a decrease in caveolar protein expression 
consistent with a role for caveolae in aggressive cell behavior. Since cell 
migration and matrix invasion require cytoskeletal rearrangements, I measured 
. the activity of the cytoskeletal-associated Rho family GTPase, Cdc42, after 
caveolin-1and cavin-1 knockdown, and observed it to be enhanced, whereas 
treatment with the Cdc42 inhibitor reduced the migratory capability of the cells 
to wild type levels. Taken together, my data supports a tumor suppressive role 
for the caveolae proteins caveolin-1 and cavin-1 in ER negative breast cancer 
through the regulation of Cdc42. Data also suggest that both caveolin-1 and 
cavin-1 are required for proper caveolae formation and function. Furthermore, it 
stresses that cavin-1 needs to be examined in the context of caveolae and cancer. 
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1. Introduction 
1.1. Cancer biology 
1.1.a. Cancer Overview 
Cancer at its simplest is the uncontrolled growth or production of 
abnormal cells in the body. In normal cells, growth and activity is a tightly 
regulated balance of homeostasis. In cancer though, there is a loss of this 
regulation leading to inappropriate and abnormal cellular function. The root of 
this abnormal cellular function lies in the DNA where changes or mutations will 
affect how the cell behaves (Cooper 2000). This genetic instability is caused by 
physical carcinogens like ionizing radiation, chemical carcinogens like cigarette 
smoke, biological carcinogens like some viral infections, or inherent genetic 
instability . . Any and all of these can bring about changes in normal homeostatic 
balance in the cell and lead to cancer. 
All people ranging from newborns to the elderly are at risk from the 
collection of diseases that makes up cancer. The total cost of premature death 
and disability from the worldwide pandemic of cancer in 2008 alone was an 
estimated $895 billion. The National Institute of Health calculated the total direct 
medical costs and indirect costs from mortality to be over 200 billions dollars 
(American Cancer Society 2013). It is estimated that roughly 600,000 people in 
the US alone are expected to die from cancer in 2013, accounting for roughly one 
quarter of all deaths in the United States. In order to fully enter the designer 
drug era and best treat cancer, a greater understanding of the molecular inner 
workings of both normal and neoplastic cells is necessary. 
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l.l.b. Hallmarks of Cancer 
Normal cells over time can accumulate genetic changes, which bring 
about a progressive evolution leading to neoplastic cells. These changes do not 
occur all at once, but slowly through the course of a lifetime of the host. As cells 
replicate, each genetic mutation that has been acquired can be passed onto the 
daughter cells, allowing mutations to accumulate. This slow accumulation is 
described as a multistep process and has become the central paradigm of cancer 
biology. The changes in cellular function that ultimately result can be grouped 
into six different classes and are have been entitled the hallmarks of cancer 
(Hanahan 2000). These six general biological functions consist of self-sufficiency 
in growth signals, a resistance to anti-growth signals, sustained angiogenesis, a 
resistance to apoptotic cell death, ~imitless replicative ability, and migration and 
invasion to surrounding tissue. Tumorigenesis begins at a single cell and as it 
gains mutations that affect the traits and functions that characterize the six 
hallmarks allowing it to become a neoplasm. When the mutated cell replicates, it 
can pass on the mutation, meaning carcinogenesis is a dynamic process 
involving side-by-side multistep evolution at the cellular level. 
Understanding the relationship between the hallmarks of cancer and the 
biology of the organism better provides an organizational framework to 
approach the complex biology of cancer. The most fundamental aspect of cancer 
both in tumor formation and clinical treatment is excessive proliferation. Normal 
cell proliferation is a tightly controlled process with a multitude of signaling 
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pathways. Replication and mitoses requires involvement from every structure of 
the cell ranging from the plasma membrane to the genetic material. Cancer cells 
gain self-sufficiency in growth signaling while resisting anti-growth signals, 
uncoupling of growth of the cell from its environment. While this does not 
ensure tumor growth, excessive proliferation is an important trait of all cancer 
cells (Hanahan 2011). 
Cancer cells, like all living things require nourishment to survive. They 
need an influx of nutrients and oxygen while metabolites and carbon dioxide 
need to be removed. Normal tissue architecture is an intricate organization of 
the extracellular matrix and many cell types, some of which make up 
vasculature. The vasculature is necessary for the efficient delivery of nutrients 
and removal of waste. As cells proliferate and a tumor develops, it will outgrow 
its normal vasculature supply. To avoid this problem, cancer cells can promote 
the growth of new vasculature. They can secrete proangiogenic factors causing 
new blood vessel growth with the growing tumor, ensuring future access to 
nourishment (Hanahan 2011). 
Cells have developed redundant mechanisms to remain in homeostatic 
balance including the induction of senescence and apoptosis. DNA damage and 
signaling imbalances are inherent consequences of tumorigenesis. In normal 
cells, aberrant signaling or DNA damage is monitored by the cell and would 
induce apoptosis, however cancer cells are able to suppress this. Cancer cells 
avoid this programmed cell death though either loss of proapoptotic elements or 
overexpression of apoptotic inhibitors (Adams 2007, Lowe 2004). These changes 
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allow the cancerous cell to grow with immunity from programmed cell suicide 
(apoptosis). 
Normal cells have a limited number of times they are able to replicate 
which is known as the Hayflick limit. In order for sizable tumors to form, cancer 
cells must have a limitless replicative capacity. They are able to achieve this 
through the expression of the DNA polymerase, telomerase. This enzyme adds 
telomere repeat segments to the end of each chromatid. The aglet like telomeres 
protect active DNA from degradation during cell replication ensuring they never 
reach the Hayflick limit (Hanahan 2011). 
While excess proliferation is often thought of as the most fundamental 
aspect of cancer, migration and invasion are the main drivers of pathogenesis 
and mortality. The progress of tumorigenesis begins with excess proliferation. 
When carcinoma in situ grows to a sufficient size, it can invade locally into 
surrounding tissue, followed by intravasation into the blood stream, and then 
extravasation into distant tissue sites where the cells can grow into 
micrometastatic lesions before becoming metastatic tumors. These steps require 
changes ranging from reorganization of the cytoskeleton to differential gene 
expression. Migrating cells require both up and down regulation of different 
attachment markers like the cadherin family in order to have proper cell-to-cell 
and cell-to-ECM attachment. The colonization of new sites requires further 
mutation as the micrometastatic lesions do not need to migrate, but instead must 
revert back to a gene expression pattern similar to the early stages of 
tumorigenesis where proliferation is a priority. The many steps and changes that 
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tumor cells undergo are characterized in cartoon form in figure 1 as is the 
possible role and expression of caveolae. Ultimately, treatment problems arise in 
· cancer because of the heterogeneity of the disease both in each tumor and 
between different patients. This diversity makes it unlikely that there will ever 
be a silver bullet medication however a greater understanding of how each 
cancer is different and how it will likely progress will helps doctors treat patients 
with the most effective drugs for their specific cancer. 
l.l.c. Balance of Oncogenes and Tumor Suppressors 
The acquirement of chromosomal abnormalities leading to cellular 
differences allows a single cell to give rise to a tumor. As the cell replicates, the 
genetic changes are passed onto the daughter cells and over time, future 
generations of cell can accumulate further changes. Most mutations that take 
place are acquired mutations, which are due to environmental insults and the 
normally low rate of imprecision of DNA polymerases. There are however 
cancer syndromes where mutated genes are inherited from parents which 
predispose the person to develop cancer. In familial adenomatous polyposis 
(F AP), germline mutations in the APC gene (adenomatous polyposis coli) result 
in the development of hundreds to thousands of benign adenomas in the large 
intestine early in the second decade of life. These adenomas develop to polyps 
and then to colorectal carcinoma by the fourth decade (Ahnen 2012). Despite 
these examples, acquired cancer syndromes make up only a minority of clinical 
cases. 
5 
Figure 1: Changes in caveolae during tumorigenesis 
Shown is a diagram representing multiple stages in tumorigenesis. Normal cells 
with an organized architecture undergo precancerous mutations (A) eventually 
leading to tumor formation (B). In order to metastasize, cancer cells must detach 
(C) from the tumor, intravasate into the blood of lymph (D) where it as 
transported to a different tissue site in the body. The cell is able to extravasate 
into the new tissue (E) where it can grow from a single cell to a metastatic lesion 
(F). Also shown is our understanding of caveolae levels at the various stages. 
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The most common type of cancer causing mutations however, are 
acquired over time. The two main types of genes that cause cancer are termed 
oncogenes and tumor suppressor genes and are frequently key regulatory genes. 
Proto-oncogenes are "normal" genes that undergo mutations, which allow them 
to become more active. This can take place through direct mutations in the gene 
leading to an increase in activity, decrease in regulation, gene duplication 
increasing in the amount of protein, or a chromosomal translocation creating an 
oncogenic fusion protein. The end result is changes in the original function of 
the protein, which in turn disrupts the homeostatic balance in the cell. One 
example of a chromosomal aberration is the creation of the Philadelphia 
chromosome. This is translocation between chromosome nine and twenty two 
resulting in the creation of the BCR-ABL fusion protein (breakpoint cluster 
region and Abelson murine leukemia viral oncogene homolog 1), which has 
elevated tyrosine kinase activity relative to wildtype ABL protein. Tyrosine 
kinases are a major group of signaling molecules that function as an "on" or 
"off" switch by transferring phosphate groups. Increased ABL activity causes 
excess cellular proliferation and is associated with chronic myelogenous 
leukemia (CML) (Van Etten 2013). Different tyrosine kinases are frequently 
hyper-activated in cancers and have a multitude of targets, including caveolin-1 
(Clenney 1989). 
Tumor suppressor genes, as the name suggests, normally inhibit the 
phenotypic changes of cancer as opposed to activating mutation in oncogenes, 
which are mutations in tumor suppressors are inactivating mutations that turn 
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them off. This removes their inhibition and regulates the different hallmarks of 
cancer. The first tumor suppressor gene identified was retinoblastoma (Rb), 
which leads to the development of retinoblastoma cancer, a rare childhood eye 
cancer. Rb is also found mutated in many other types of adult cancers (Cooper 
2000). Rb normally regulates the cell cycle by inhibiting progression from G1 to 
the S phase by binding to transcription factors. When Rb is lost, the transcription 
factors are able to promote progression through the cell cycle increasing growth 
rate of the cell. 
The dichotomy that genetic elements are either tumor suppressors or 
oncogenes is simple framework to understand the biology of cancer, however the 
actual regulation of cellular function is not so black and white. Some elements of 
cancer have shown a Janus-faced role, acting as both an oncogene and tumor 
suppressor, i.e., depending on the context, they can either suppress or promote 
tumorigenesis. The transforming growth factor (TGF) pathway demonstrates the 
dichotomy of these pathways. TGF-131 pathway has a context dependant role in 
cancer progression. TGF-131 is a cytokine that primarily signals through their cell 
surface receptor to the intracellular mediators, the SMAD (mothers against 
decapentaplegic) proteins and in early tumor development, is able to inhibit 
proliferation and induce apoptosis (Ikushima 2010). However, in some contexts 
in human cancer it has been shown to promote the epithelial to mesenchymal 
transition and promote metastasis (Pardali 2007). Mouse studies have supported 
this dual role for TGF-131. Studies show that suppression of TGF-131 signaling 
increases tumor development suggesting a tumor suppressive role and that 
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overexpression of TGF-~1leads to the development of malignant spindle cell 
carcinomas (Zhang 2010). The dual role of some elements of cancer can be 
partially explained by the great complexity of the cell. The different context of 
the cell, be it tumor stage, tissue type, or gene dosage can modulate the exact 
function of genes in cancer. 
l.l.d. Breast Cancer 
Breast cancer is the most common type of invasive cancer in women, 
comprising twenty nine percent of all new cases. Women in the United States 
have roughly a one in eight chance of being diagnosed with breast cancer at 
some point in their lives (Ahnen 2013). The two main types of breast cancer are 
lobular and ductal carcinoma. Lobular carcinoma originates in the terminal duct 
lobular units, or the milk producing part of the breast. Ductal carcinoma arises 
from the lactiferous ducts, which transport milk from the terminal ductal lobules 
to the nipple. Invasive ductal carcinoma accounts for eighty percent of all breast 
cancers. 
In the context of the major hallmarks of cancer, breast cancer functions 
similar to other types and is classified by grade, stage, and histopathology. One 
unique trait however, is the receptor status of the tumor. Estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2) are three receptors that are used to classify breast cancer and contribute 
in different ways to tumor function and potentiate treatment methodology. 
Many breast tumors, unlike other tumors, are sensitive to estrogen in that 
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estrogen and progesterone drives their growth. HER2 has been shown to effect 
proliferation and apoptosis and is associated with a worse prognosis. While ER, 
PR, and HER2 are able to drive different aspects of tumorigenesis, they are also 
critical to clinical management. Hormonal therapy includes antagonists to the 
estrogen receptor, blocking the production of estrogen, and targeted antibody 
therapy to HER2 is highly effective creating a positive clinical outcome. These 
treatments are not available in triple negative breast cancer therapy, which are 
tumors that lack the above named pharmacological targets and are more 
aggressive, have a poorer prognosis, and have a higher relapse rate. 
Understanding the molecular biology of triple negative breast cancers is 
necessary to find new targets for improved therapy. 
As cells grow and transform, changes take place not only in transcription 
and translation but also in the physical shape. When cells are motile including 
during the intravasation and extravasation aspects of the invasion process, 
changes to the cytoskeleton and plasma membrane are necessary. Organization 
and localization of different cell surface proteins are required for the cell to 
undergo the changes in cancer progression. Caveolae microdomains on the 
plasma membrane have been implicated in a variety of cellular functions and in 
tumorigenesis, creating an interesting avenue for research to better understand 
the intricacies of cancer. 
1.2. Caveolae 
1.2.a. Plasma Membrane Organization and Lipid Rafts 
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For forty years, the Singer-Nicholson fluid mosaic model has been used to 
explain the plasma membrane (Singer 1972). In this model, lipid and protein 
components easily move within the passive aqueous phospholipid bilayer 
however this is a passe concept that fails to capture the actually complex 
membrane composition. The plasma membrane is inhomogeneously organized 
into microdomains with a different structure and physiological function than the 
surrounding membrane (Cooper 2000). One such area is the lipid raft. Lipid 
rafts contain phospholipids with saturated hydrocarbon chains, sphingolipids, 
and high levels of cholesterol, creating densely packed areas of the plasma 
membrane. The differences in lipid components make lipid rafts insoluble in 
nonionic detergents. Certain proteins have been shown to concentrate in these 
areas including glycosylphosphatidylinositol (GPI)-anchored proteins, G 
proteins, SRC (sarcoma) family tyrosine kinases, and cholesterol binding proteins 
(Reeves 2012). Subsequently, lipid rafts have been shown to play an important 
role in signal transduction (Pike 2003, Lingwood 2010). 
1.2.b. Caveolae 
Caveolae are a subset of lipid rafts and were first described 
morphologically in the 1950's via electron microscopy as 50-lOOnm flask or 
omega shaped invaginations on the plasma membrane (Palade 1953) (Figure 2). 
They are present on a variety of tissue type, most abundantly on adipocytes, 
endothelial, and muscle cells. Caveolae are comprised of two classes of proteins, 
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Figure 2: Current model of caveolae. '\ 
Shown is a cartoon diagram representing our current understanding of the 
formation of caveolae. The integral membrane proteins, the caveolins are 
inserted into the inner plasma membrane and cause the characteristic curvature 
of caveolae. In the cytoplasm, the cavin family of proteins that are also required 
for proper caveolae formation bind to the caveolins. Evidence suggests a direct 
connection then from the cavin proteins to the cortical cytoskeleton, specifically 
filamin (Stahlut 2000). Actin has also been implicated (Breen 2012). 
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the integral membrane caveolins (Figure 3A) and caveolae associated proteins, 
the cavins. 
(Figure 3B). Functionally, caveolae have been implicated in endocytosis, 
signal transduction, mechanotransduction, and cholesterol and lipid homeostasis 
(Parton 2007). Mutation of the caveolar proteins in mammals has led to a variety 
of diseases ranging from lipid disorders, muscle dystrophies, and cancers (Liu 
2008, Razani 2002, Minetti 2098, Hayashi 2009, Carver 2003). 
Caveolae are relatively stable structures; immunofluorescence using 
green-fluorescent protein ( GFP) tagged caveolin-1 shows a slow turnover at the 
plasma membrane. However, under certain conditions, caveolae can be induced 
to undergo a non-clathrin mediated endocytosis (Kiss 2012). The main ligands 
internalized are integrins and glycosphingolipids, supporting a role for caveolae 
in the regulation of cell attachment. Specifically, clustering of active j31-integrin 
will initiate endocytosis although the exact relationship between caveolae and 
other integrins is still under investigation (Shi 2008). Interestingly, it has been 
shown that caveolar endocytosis can also be hijacked for viral and bacterial cell 
entry. These include Simian virus 40, polyoma virus, echovirus1, human 
immunodeficiency virus, respiratory virus, and some species of the bacterium 
Escherichia coli. The definitive clinical importance of caveolar endocytosis in the 
pathogenesis of these organisms is still not understood (Bastiani 2010). 
Research has supported a role for caveolae in cellular signaling. They are 
understood to act as a scaffolding that can bind and sequester signaling 
machinery, functionally creating specialized micro-domains for the assembly of 
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Figure 3: The Caveolin and Cavin Families of Proteins 
A schematic representation showing the different domains, the amino acid 
number, and the structural similarities of the (A) caveolin and (B) cavin protein 
families. OD: oligomerization domain. CSD: caveoling scaffolding domain. 
TMD: transmembrane domain. LZ: leucine zipper. NLS: nuclear localization 
signal. PEST: proline (P), glutamic acid (E), serine (S), and threonine (T). 
Adapted from Bastiani 2009 and Norica 2012. 
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signaling complexes. G protein-coupled receptors (GPCRs), receptor tyrosine 
kinases, endothelial nitric oxide synthase (eNOS), GTPases, and steroid hormone 
receptors like ERa, progesterone, and androgen receptors have all been shown to 
localize or more likely interact with the protein components of caveolae (Patel 
2008, Bastiani 2010). This diverse variety of different signaling pathways 
suggests that caveolae are important for proper cell function, though it unlikely 
that caveolae are master regulators of signaling as knockout mice that lack 
caveolae are still viable. Many of the reports that link signaling molecules to 
caveolae do so through immunoprecipitation however functional data is often 
lacking, casting further doubt on the proposed ubiquitous signaling effects in cell 
(Parton 2007). 
While many of the functions of caveolae remain controversial, one of the 
original hypotheses, that caveolae are involved in mechanosensation, has 
recently gained evidential support. Many of the tissues first observed to contain 
caveolae were blood vessels, muscle, and gall bladder epithelium, all tissue that 
constantly are subjected to sheer stress and mechanical stretching. It has been 
shown that osmotic swelling as well as forced elongation of muscle fibers results 
in the loss or flattening of caveolae suggesting an important role helping the 
tissues handle stress (Nassoy 2012, Sinha 2012). The cell has evolved to deal with 
tension and stress in many ways ranging from opening of channels in order to 
adapt to osmotic differences to recruitment of new membrane. However 
instantaneous adaptation to fluctuations in membrane tension take place in order 
to avoid acute injury. It has been shown that caveolae are able to do this through 
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the flattening of caveolae (Sinha 2012). This passive and reversible change 
buffers the membrane tension by releasing the membrane reservoir present in 
caveolae. 
Of the many tissue types that caveolae are normally present in, the highest 
concentration is in primary adipocytes where they can make up fifty percent of 
the cell surface (Thorn 2003). The adipocyte is not only the main site in the body 
for energy storage but also critical for fatty acid release and metabolic 
homeostasis. This suggests that caveolae are important in the regulation of lipids 
and cholesterol. One hypothesis is the caveolae and the lipid raft are important 
to buffer fatty acids as they are mild detergents and at high concentrations, can 
damage normal membranes. (Simard 2010) Further support comes from studies 
manipulating caveolin-1. When caveolin-1 is expressed in cells with no 
endogenous caveolin-1, uptake of fatty acids and cholesterol turnover was 
increased (Meshulam 2006). The many roles attributed to caveolae are not 
mutually exclusive and very well may be due to the individual interactions of the 
caveolin and cavin family of proteins as well as the caveolae ultrastructure. 
1.2.c. The Caveolin Family 
The caveolin family is composed of three members (caveolin 1-3) and is 
the principal component of caveolae. These small18-24 kilodalton proteins have 
significant homology. Caveolin-1 shares a 58% sequence similarity with 
caveolin-2 and an 85% similarity with caveolin-3. All three have a signature 
motif, an invariant "FEDVIAP" stretch in theN-terminal domain. The caveolins 
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are integral membrane proteins with a 33 amino acid hydrophobic domain that 
forms a hairpin loop and inserts into the plasma membrane while the both the N-
terminus and C-terminus face the cytoplasm (see Figure 2). Caveolin-1 forms 
homo- and hetero-oligomeric structures with caveolin-2. It is estimated that 144 
individual components are necessary to form a single caveola (Pelkmans 2005). 
Caveolin-1 and -2 are located on chromosome 7q31.1 and share a similar tissue 
distribution predominantly in adipocytes, epithelial, and endothelial cells. In 
these tissues caveolin-1 is necessary for the formation of caveolae (Williams 
2004). The role of caveolin-2 is yet to be fully understood but it is not necessary 
for caveolae formation (Parolini 1999). Caveolin-3 is on found on chromosome 
3p25 and is expressed in skeletal, cardiac, and smooth muscle cells and is critical 
for caveolae formation in muscle tissue (Williams 2004, Serra 2009). 
1.2.c.l. Caveolin-1 
Caveolin-1 was the first structural protein to be identified as a component 
of caveolae. Cloning of caveolin-1 showed that it was identical to VIP21 (vesicu-
lar integral-membrane protein of 21 kilodaltons), which was originally identified 
as an integral membrane protein in trans-golgi transport vesicles (Kurzchalia 
1992). It is understood that the broad function of caveolin-1 comes from the 
cytoplasmic presence of the N-terminus and C-terminus, particularly a twenty 
' 
amino acid so-called scaffolding domain on that amino terminus. The 
scaffolding domain has been proposed to bind G-protein subunits, tyrosine 
kinases, endothelial nitric oxide synthase, and small GTPases (Reeves 2012). 
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These studies often used co-immunoprecipitation to make the connection but the 
results have been called into question as more functional assays often failed to 
support the findings. The proposed caveolin scaffolding domain that would be 
responsible for binding of the signaling molecules has been suggested to also be 
a membrane binding protein and may be buried in the plasma membrane 
blocking any other potential binding (Parton 2007). 
Caveolin-1 binds cholesterol, which is a critical interaction for caveolae 
formation. Depleting cholesterol from cells by inhibition of the enzyme 3-
hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), the rate 
limiting step in endogenous cholesterol formation by statin treatment or 
increased cholesterol efflux by methyl-beta-cyclodextrin treatment results in a 
loss of morphological caveolae while repletion of cholesterol leads to a 
reformation of the caveolae (Hailstones 1998). The caveolin-1 promoter contains 
two sterol regulatory elements that control transcription though the free 
cholesterol induced SREBP1 (sterol regulatory element-binding proteins) further 
supporting a role of caveolin-1 in cholesterol regulation (Frank 2006, 
Radhakrishnan 2008). 
The creation of caveolin-1 knockout mice has contributed greatly to our 
understanding of caveolae function (Razani 2001, Razani 2002). These mice are 
viable, fertile, show a loss of morphological caveolae in non-muscle tissue, have 
decreased expression of the other caveolin proteins, and develop a host of 
pathological conditions (Bastiani 2010). They exhibit severe cardiac problems 
notably cardiac hypertrophy, reduction in ventricular systolic function, and right 
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ventricular dilation. These features, particularly the cardiac hypertrophy, lead to 
early heart failure in the knockout mice. There is also increased development of 
neointimal hyperplasia (Cohen 2003, Park 2003). The intima is the innermost 
layer of the blood vessel and hyperplasia results in luminal narrowing which 
normally would lead to atherosclerotic consequences, yet caveolin-1 null mice 
are resistant to the development atheromas presumably to changes in fatty acid 
and cholesterol release. 
Caveolin-1 knockout mice present with drastic metabolic differences 
compared to wildtype controls. They are lean, hyperlipidemic, and have small 
adipocytes. This reduced adiposity is not due to increased fattiness in other sites 
like muscle or liver. Coupled with their leanness is a resistance to diet induced 
obesity and impaired insulin signaling (Razani 2002A). The exact role of 
caveolin-1 in this metabolic phenotype is not yet entirely understood. 
Caveolin-1 is highly expressed in type 1 pneumocytes. The caveolin-1 
knockout mice expectedly have severe pulmonary problems. They have a 
modified pulmonary anatomy with reduced alveolar spaces, fibrosis, and 
hypercellularity. Cav1 has been shown to be decreased in mouse models of 
pulmonary hypertension (Drab 2001). Lung pathology is also believed to be a 
main contributor to the early mortality in these mice. 
The diverse phenotype of the knockout suggests that caveolin-1 plays a 
part in human disease. This was shown to be true in Berardinelli-Seip congenital 
lipodystrophy (BSCL), a rare (1 in 10 million) autosomal recessive disorder 
characterized by near total absence of adipose tissue, severe dyslipidemia, and 
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insulin resistance (Kim 2008). Later manifestations include acanthosis nigricans 
(hyperpigmentation and thickening of skin), hepatomegaly, metabolic syndrome, 
and cardiovascular problems including cardiac hypertrophy and arterial 
hypertension (Magre 2001). Most presentations of this disease are due to loss of 
the enzyme 1-acylglycerol-3-phosphate acyltransferase-beta however some cases 
are due to an unknown mechanism (Maldergem 2003, Garg 2009). It has been 
shown in these unknown cases that there is a homozygous nonsense mutation 
(p.Glu38X) in caveolin-1leading to a loss of expression (Kim 2008). This 
supports a role for caveolin-1 in adipocyte function and metabolic signaling not 
just in mice but also in human genetics. Multiple somatic mutations have been 
discovered in cancers but this will be discussed in-depth at a later stage. 
1.2.c.2. Caveolin-2 
Caveolin-2 was discovered a few years after caveolin-1 through 
microsequencing of a 20 kilodalton protein that was co-purified from caveolin-1 
emiched microdomains in murine adipocytes. Caveolin-2 expression is tightly 
coupled with caveolin-1 and requires caveolin-1 for the formation of hetero-
oligomers. Unlike caveolin-1, caveolin-2 is unable to form homo-oligomers and 
also does not directly bind cholesterol (Reeves 2012). These similarities and 
differences suggest that caveolin-2 functions as an accessory protein with 
potentially redundant function. However, the caveolin-2 knockout mouse shows 
otherwise. The caveolin-2 knockout presents with the same lung pathology seen 
in the caveolin-1 knockout while caveolin-1 expression and caveolae formation is 
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similar to wildtype levels (Razani 2002B). This suggests that the lung pathology 
in the caveolin-1 knockout mouse is due to the subsequent loss of caveolin-2 and 
not caveolin-1, complicating our understanding of the exact function of caveolin-
2. 
The caveolin-2 knockout mouse also presents with a skeletal muscle 
phenotype. At a young age skeletal muscles contain tubular aggregate 
formations and mitochondrial proliferation/ aggregation (Schubert 2007). 
Tubular aggregates are the primary feature of a rare genetic disorder and a 
nonspecific structure in multiple other muscular pathologies. They are 
crystalline like structures found between myofibrils whose function is not yet 
understood (Schiaffino 2012). Caveolin-2 however, is not expressed in 
differentiated muscle. It thought that the muscular pathology might be due to 
defects in the muscle precursor cells like myoblasts or from disrupted muscle 
vasculature (Schubert 2007). 
1.2.c.3. Caveolin-3 
The third caveolin family protein to be discovered was caveolin-3, which 
was found through eDNA library screening from sequence homology to 
caveolin-1. Caveolin-3 has a different tissue distribution from the rest of the 
family and is muscle specific. Similar to caveolin-1, caveolin-3 is able to form 
homo-oligomeric complexes and drive caveolae formation (Williams 2004, 
Reeves 2012). 
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The caveolin-3 knockout mouse, while viable, expectedly has pronounced 
muscle pathologies. In skeletal muscle, muscle degeneration, T-tubule 
abnormalities, and mononuclear cell infiltration are observed. In cardiac muscle 
there is pronounced cardiac hypertrophy, fibrosis, and reduced fractional 
shortening (Woodman 2002). There is also a metabolic phenotype. Caveolin-3 
null mice have increased adiposity, are insulin resistant, have decreased glucose 
uptake, and loss of insulin receptor upon insulin stimulation (Capozza 2005). 
Together the knockout mouse suggests an important role for caveolin-3 in 
muscle physiology as well as in glucose metabolism and insulin receptor 
stability. 
Human mutation of caveolin-3 have been discovered that lead to 
numerous muscular dystrophy phenotypes. The first identified was an 
autosomal dominant limb-girdle muscular dystrophy (LGMD) type lC which is 
a progressive weakness in the hips and shoulders resulting in dependence on a 
wheelchair by age twenty-thirty (Mercier 2009). Other mutations of caveolin-3 
have been seen in autosomal dominant rippling muscle disease, hyper-CKemia, 
distal myopathy, familial hypertrophic cardiomyopathy, arrhythmogenic 
syndrome long QT syndrome, and sudden infant death syndrome (Serra 2009). 
The exact mechanism for how caveolin-3 causes these different diseases is 
unknown. It is understood however that the mutations are often heterogeneous 
and act in a dominant negative manner, blocking trafficking of wild type 
caveolin-3 and causing retention of the protein in the Golgi (Williams 2004, 
Reeves 2012). 
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1.2.d. The Cavin Family 
For many years it was accepted that caveolin-1 was both necessary and 
sufficient for caveolae formation. The cavin family of proteins is a recent 
addition to the caveolae field demonstrating that the cavins are critical for both 
the formation and function of caveolae. This caused a change in the paradigm 
that while caveolin-1 is necessary for caveolae formation, it is not sufficient. The 
family is composed of four members; cavin-1 (formerly polymerase I and 
transcript release factor) (Mason 1997), cavin-2 (formerly serum deprivation 
protein response, SDPR) (Gustincich 1993), cavin-3 (formerly SDPR-related gene 
product that binds to C kinase) (Izumi 1997), and cavin-4 (muscle restricted 
coiled-coiled protein) (Bastiani 2009). Cavin-1 was the first to be discovered to be 
present in caveolae and thanks to similar homology, the other cavins were 
discovered (Hi112008, Liu 2008). The cavin family members all contain leucine 
zipper-like domains for protein-protein interaction and PEST domains (proline, 
glutamic acid, serine, and threonine rich domains), which are involved in 
proteolytic degradation. Cavin-1 has a unique domain among the cavin family, a 
putative nuclear localization signal. This signal fits considering that cavin-1 was 
originally identified as a regulator of RNA polymerase though recent data 
supports a predominant role outside the nucleus. All cavins migrate 10-15kDa 
higher then predicted from their primary structure during SDS-PAGE (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis) in part due to post-
translational modification including phosphorylation. The members of the cavin 
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family have also been shown to bind phosphatidylserine, which may be 
important for their lipid raft localization (Hansen 2010, Briand 2011). 
The tissue distribution of cavin 1-3 mimics that of caveolin-1. The two 
exceptions are cavin-1 is also found in skeletal muscle and cavin-3 may be 
present in liver and brain. Cavin-4 is similar to caveolin-3 in that they are muscle 
specific. Caveolae formation is dependant on both caveolin-1 and cavin-1 
expression while cavin-2 and cavin-3 are important for stability and function of 
caveolae. It has been described through co-immunoprecipitation that the cavin 
family forms a multimeric complex in caveolae though the exact connection to 
the- caveolins is not completely understood (Bastiani 2009). 
1.2.d.i. Cavin-1 
Cavin-1 was first identified in a yeast two-hybrid screen Gansa 1998, 
Hasegawa 2000). Transcription termination factor (TTF)-1 was used as bait, 
which is involved in the polymerase 1 mediated transcription of ribosomal 
RNAs. Originally it was shown that cavin-1 interacts with both TTF and RNA 
polymerase 1 and is a factor involved in the disassociation of paused complexes. 
The original work supports the putative nuclear localization signal but more 
recent work has predominantly described cavin-1 to be present at the plasma 
membrane (Vinten 2001, Vinten 2005). 
Cavin-1 is enriched in caveolae and is critical to caveolae formation. 
Depletion of cavin-1 results in a morphological loss of caveolae and a decrease in 
protein expression of all cavins and caveolins (Hill2008, Bastiani 2009). 
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Conversely, an increase in cavin-1 content will increase caveolin-1 expression 
and the number of caveolae. 
The cavin-1 knockout in zebrafish (Hill 2008) and mice (Liu 2008) both 
show a loss of caveolae along with reduction of expression of the caveolin family 
(Hi112008). The knockout mouse has dyslipidemia, hypertriglyceridemia, 
hyperinsulinemia, reduced adipose tissue, glucose intolerance, and a muscular 
dystrophy (Liu 2008). This is similar to the caveolin-1 I caveolin-3 double 
knockout mouse but expected when it is considered that the tissue distribution of 
cavin-1 mimics the combination caveolin-1 and caveolin-3 (Park 2002). 
Similar to the caveolin proteins, pathologic issues seen in the cavin-1 
knockout mouse are recapitulated in a few rare genetic cases implicating cavin-1 
in human disease. Hayashi et al in 2009 performed a genetic screen on 2745 
muscular dystrophy specimens in order to explore the relationship between 
caveolin-3 and cavin-1. They were able to find five patients with BSCL who were 
deficient in caveolin-3 protein yet no caveolin-3 mutations. These patients did 
however have frameshift mutations in cavin-1 that severely truncated the 
protein. All five patients also had a generalized muscular dystrophy along with 
BSCL. Cavin-1 has also been implicated in human liposystrophies. Cavin-1 was 
the most probable candidate in congenital generalized lipodystrophy subtype 4 
that presents with a near total loss of body fat and multiple myopathies 
(Dwianingsih 2010, Rajah 2010, Shastry 2010). These studies support a role for 
cavin-1 in human disease that mimics what is observed in mice. 
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The genomic location of each of the cavins supports our hypothesis and 
predicts tumor suppressive roles. Cavin-1 is located at 17q21.2, an area that has 
been implicated in human disease. Genome wide association studies have 
implicated this locus in type-one diabetes (Barrett 2012). In population studies, 
variants at this region have been associated with intracranial volume and the 
subsequently the inability to reach maximal brain size (Ikram 2009). It should be 
noted that this does not ensure that cavin-1 is the driver in these phenotypes. 
Also present at the gene locus 17q21.31 is the commonly known mammary 
tumor suppressor gene, BRCA1 (breast cancer gene 1) (Miki 1994). More 
research needs to be done to better understand these genetic ·and pathologic 
connections in breast cancer. 
1.2.d.2. Cavin-2 
Cavin-2 was originally named SDPR because serum deprivation results in 
a higher expression of cavin-2 in cell lines (Gustincich 1993). It was identified as 
both a phosphatidylserine binding protein in human platelets and also as a 
substrate for protein kinase C (PKC). When it was shown to localize to the 
plasma membrane at sites of caveolae and directly bind cavin-1 as member of the 
multimeric complex, its name was changed to cavin-2 (Hill 08). Knockdown of 
cavin-2 results in loss of caveolae and decreased expression of cavin-1 and 
caveolin-1 suggesting cavin-2 is an important part of the multimeric complex 
(Hansen 2009). Unlike cavin-1, overexpression of cavin-2 does not increase the 
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number of caveolae. Together with data from cavin-1, I see that cavin-2 plays a 
different role but is necessary for the proper function and formation of caveolae. 
Functionally, cavin-2 has been show to be cholesterol responsive. 
Depletion of cholesterol results in proteasomal degradation of cavin-2 and 
movement of cavin-1 to the cytosol. Upon cholesterol repletion, caveolae return 
along with newly translated cavin-2 (Breen 2012). Functionally, cavin-2 has also 
been described to be important for membrane curvature in caveolae. 
Overexpression leads to a tubulation of the plasma membrane as seen by 
immunofluorescence and caveolae appear elongated or distended by electron 
microscopy (Hansen 2009). 
The cavin-2 gene is located at 2q32-q33, a region also implicated in 
disease and cancer. The 2q32-q33locus has also been implicated in the 
eponymous chromosome 2q32-q33 deletion syndrome that leads to severe 
mental retardation, microcephaly, and craniofacial dysmorphism (Glass 1989, 
Van Buggenhout 2005). In cancer, this region is described through a genome-
wide linkage screen to cause Jass syndrome (or familial serrated neoplasia), a 
rare form of hereditary colorectal cancer (Roberts 2011). Interestingly, the 7q31 
locus, the site of caveolin-1, has also previously been implicated in colorectal 
cancer (Neklason 2008). 
1.2.d.3. Cavin-3 
Little is known about the cavin family protein, cavin-3. It was identified 
in a screen as a PKCdelta binding protein and coimmunoprecipitates with cavin-
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1 and cavin-2 and localizes to the adipocyte plasma membrane at sites of 
caveolae (Bastiani 2009). Cavin-3 however has a broader tissue distribution 
suggesting that it has a physiological role outside of caveolae (Mcmahon 2009, 
Briand 2011). 
Functionally, not much is known about cavin-3 except that it has been 
implicated in endocytosis and intracellular transport. During caveolae budding, 
cavin-3 remains associated with caveolin-1 in the transport vesicles and 
knockdown of cavin-3 decreases the intracellular movement of caveolin-1. In 
humans, cavin-3 is on 11 p 15.5-15.4, which is a predicted tumor suppressor region 
that is inactivated in lung and breast cancers (Mcmahon 2009). 
The cavin-3 gene is located at llp15.4, a putative tumor suppressor locus 
that shows loss of heterozygosity in multiple cancers (Karnik 1998). Specifically 
in breast cancer the locus is most frequently lost in ER negative, high-grade 
tumors, and contributes to late stage cancer progression (Ali 1987, Winqvist 
1995). It has also been shown in breast cancer metastases isolated from the brain 
that this region is disrupted, suggesting a cavin-3 may be a driving force in the 
ability to metastasize (Wikman 2012). 
1.2.d.4. Cavin-4 
Cavin-4 was identified as a cavin family member through its sequence 
homology (Bastiani 2009). As a muscle restricted protein, cavin-4 is similar to 
caveolin-3 in its tissue distribution. It also colocalizes with caveolin-3 at the 
plasma membrane at sites of caveolae. Functionally, cavin-4 has been connected 
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to the Rho/ROCK (Rho-associated protein kinase) signaling pathway and been 
shown to influence skeletal muscle differentiation (Bastiani 2009). Interestingly, 
cavin-4 has been implicated in human disease. In mice and human with a 
caveolin-3 defect that suffer from rippling muscle disease, cavin-4 is also 
disrupted supporting a solid role for the cavin family of proteins in human 
disease (Mercier 2009). 
The cavin-4 gene is located at 9q31.1 however very little has been shown 
to implicate cavin-4 in cancer. Unlike the cavin 1-3, amplification of the cavin-4 
locus has been associated with poor survival in patients with colorectal cancer 
(Saweboot 2011). This suggests that at least one oncogene is present in this 
region. However this observation is not universal as it is deleted in early-stage 
gastric cancer (Kakinuma 2004). As the cavin-4 protein is the muscle specific 
isoform of the cavin family, the possible oncogenic role of the proteins at this 
locus is unlikely to be due to cavin-4. 
1.3. Caveolae and Cancer 
1.3.a. Caveolin-1 in Cancer 
Over 20 years of research into the role caveolae in cancer has primarily 
focused on caveolin-1. It was first observed to be the major tyrosine 
phosphorylated target in cells transformed by the oncogene v-src that suggested 
it has an active role in tumorigenesis (Clenney 1989). The first direct evidence 
later then came from NIH-3T3 cells. When these cells were transformed with 
oncogenes like Ras and Abl there was a decrease in caveolin-1 expression. 
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Interestingly, the size of soft agar colonies inversely correlated with the 
expression levels of caveolin-1. It was also shown that when caveolin-1 was re-
expressed in these transformed cells, it inhibited colony growth (Koleske 1995, 
Engelman 1997, Galbiati 1998). Later work went on to show that transformation 
with a broad range of oncogenes produces the same effect on caveolin-1 (Razani 
2000). This suggested that changes of caveolin-1levels during cellular 
transformation are directly tied to the cancer pathology. This finding was further 
supported in other cell lines. In prostate cancer cell lines, it was shown that 
caveolin-1 participates in a phosphatidylinositol-3-kinase and protein kinase B 
(PI3/ AKT) dependent upregulation of growth factors including vascular 
endothelial growth factor (VEGF), TGF-B1 and fibroblast growth factor 2 (FGF2) 
(Li 2009). In glioblastoma cells, reduction of caveolin-1levels led to a more 
aggressive phenotype while upregulation of caveolin-1 decreased proliferation 
and invasiveness through integrin regulation (Martin 2009). 
Clinically, caveolin-1 expression becomes even more complicated. 
Pathologic analysis of patient tissues of pancreatic (Suzuoki 2002), esophageal 
(Ando 2007, Kato 2002), breast, renal Uoo 2004, Carnpbell2003), brain (Barresi 
2006), lung (Ho 2002, Ho 2007, Moon 2005, Yoo 2003), and prostate (Yang 2005, 
Yang 1999) show up-regulation is associated with reduced survival suggesting 
an oncogenic function. Conversely, caveolin-1 is decreased in breast (Sagara 
2004), lung (Sunaga 2004, Wikrnan 2004), ovarian (Wiechen 2001, Davidson 
2001), and thyroid (Aldred 2003) tumors suggesting a tumor suppressive role. 
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As the role of caveolin-1 is inconsistent across different cancerous tissues, it is 
difficult to draw an exact conclusion to its function. 
1.3.b. Caveolin-1 in Breast Cancer 
Focusing on the details of caveolin-1 in breast cancer, there is a dichotomy 
between tumor suppressor and oncogene. An overview of human breast cancer 
cell lines shows that caveolin-1 is reduced when compared to normal mammary 
epithelial cells, suggesting that the putative tumor suppressor is lost in 
tumorigenesis. Manipulation of caveolin-llevels supports this hypothesis. 
Overexpression of caveolin-1 in the breast cell lines has a variety of effects. In 
T47D cells, there is a decrease in proliferation and soft agar colony formation 
(Lee 1998). Overexpression in MCF7 cells results in a decrease in proliferation, 
soft agar colony formation, anoikis, and invasion as well as decreased MMP2 
(matrix metalloproteinase) activity and ERK (extracellular signal-regulated 
kinase) signaling (Fiucci 2002). Similar results are seen in primary cells. Primary 
mammary epithelial cells derived from the caveolin-1 knockout mouse exhibit a 
drastically different phenotype from wildtype cells when grown three-
dimensional matrigel system. Wild type cells grow a regular spheroid with a 
lumen while the knockout cells have a fully filled irregular shape with increased 
ERK signaling and MMP activity (Sotgia 2006). 
While most in vitro data in breast cancer cell lines suggest a tumor 
suppressive for caveolin-1, some studies have shown the opposite. 
Overexpression of caveolin-1 in the Hs578T cell line causes in increase in soft 
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agar colony formation and decreased apoptosis (Wu 2007). Caveolin-1 has been 
implicated in multidrug resistance. The doxorubicin resistant strain of MCF7 
cells has an increased expression of caveolin-1 and an increased density of 
caveolae at the plasma membrane (Lavie 2001). The exact mechanism remains 
unknown but the resistance may in part be due to an increase is cholesterol efflux 
pathways at sites of caveolae. This trait is not universal across all cell lines as an 
increase is caveolin-1 in Hs578T breast cells does not result in a multidrug 
resistant phenotype (Cai 2004). 
Animal studies using tumor xenografts and caveolin-1 knockout mice 
have furthered our understanding of the in vivo tumor suppressive role of 
caveolin-1. MCF7 derived tumor xenografts stably transfected with caveolin-1 
demonstrated growth inhibition and delayed progression when compared to 
wild type (Wu 2008). The caveolin-1 knockout mouse has been used in multiple 
·ways, which demonstrate its tumor suppressive capabilities. First it was treated 
with the carcinogen 7,12-dimethylbenzanthracene (DMBA), leading to increased 
tumor formation compared to wild type (Capozza 2003). Secondly, the caveolin-
1 knockout mouse was crossed with the tumor prone mammary tumor virus-
polyoma middle T model mouse (MMTV-PyMT) which showed that loss of 
. caveolin-1 resulted in an increased development of multifocal dysplastic lesions 
as well as an increased tumor burden with changes in ERK-1 I 2 signaling and 
MMP2 and 9 secretion when compared to MMTV-PyMT alone (Williams 2003). 
These data support caveolin-1 as a tumor suppressor however the caveolin-1 
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knockout mice do not spontaneously develop mammary tumors, which may 
downplay the potential impact for caveolin-1in tumorigenesis. 
The human genetic location suggests caveolin-1 is a tumor suppressor. 
Caveolin-1 is on the q31.1 region of chromosome 7, adjacent to the D7S522 in the 
fragile chromosome site, a commonly deleted region in cancer. Examining 
primary breast tissue dissections in a Japanese patient population, it was found 
that 16% of all samples had a loss of function mutation in the transmembrane 
domain of caveolin-1 (Hayashi 2001). A later study in the United States 
narrowed down the population and found this mutation to be in over one third 
of ER+ breast cancers while entirely lacking in ER- tumors (Li 2006). This proline 
to leucine mutation results in caveolin-1 not being targeted to the plasma 
membrane, remaining in the ER/ golgi, disrupting its physiological function and 
in this situation, promotirig tumorigenesis. Human studies also provide 
evidence in the other direction. A studying looking at nearly a thousand patient 
samples showed that caveolin-1 is overexpressed in the metastatic population. 
In a subset of these metastatic cases, the caveolin-1 gene has been amplified 
suggesting that it may be a driver behind the oncogenesis (Savage 2007). Of 
similar note, the caveolin-1 gene promoter has been described to be 
hypomethylated (Rao 2012). This would allow for increased transcription and 
expression. Thus far there is compelling evidence that caveolin-1 can function as 
both a tumor suppressor and oncogene. It has been hypothesized that varying 
roles of the caveolar proteins in cancer are influenced by the tumor stage as well 
as other molecular effectors involved including the cavin proteins. 
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1.3.c. Cavin-1 in Cancer 
·The cavin proteins have only recently begun to be explored in the context 
of cancer. In the prostate, cavin-1 expression is decreased in LNCaP and PC3 
cancer cell lines. When surgical samples of prostate cancer were compared to 
benign prostatic hyperplasia samples, cavin-1 expression matched the cell lines 
and showed a decrease in the cancerous population (Gould 2010). Another 
group looking further into the function of cavin-1 in prostate cancer showed that 
expression of cavin-1 in PC3 cells decreased migration reduced MMP9 
production. The reduction of MM9 also took place after expression of cavin 2-4 
(Aung 2011). In breast cancer, cavin 1-3 RNA and protein is decreased in MCF7 
and MDA-MB-231 cell lines compared to the immortalized MCF10A cell line (Bai 
2012). Their data extended into human tissue as cavin expression is decreased in 
tumors compared to the tumor adjacent tissue in a majority of cases examined. It 
is suspected that the decrease in cavin-1 is due to promoter methylation. 
Together the data suggest that the cavin family of proteins deserves further 
examination in the pathology of cancer. 
1.4. The Cytoskeleton and Signaling 
1.4.1. Cytoskeletal Changes 
The cytoskeleton is the cellular scaffolding that helps make up the 
structure and shape of the cell. It is also critical to cellular motility, intracellular 
transport, chromosomal separation, and cellular organization. The cytoskeleton 
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is an organized network of three protein filaments: microtubules, actin filaments 
(also called microfilaments), and intermediate fibers. Microtubules are polymers 
of alpha and beta tubulin that are important for maintaining cell structure, cell 
division, intracellular transport, and make up flagella and cilia (Howard 2003). 
Actin filaments composed primarily of actin polymers, are critical to cell 
structure and cellular motility (Chhabra 2007). Intermediate filaments are the 
most diverse group of the three making up laminins, keratins, neurofilaments, 
and vimentins and are predominantly used for mechanical tension (Herrman 
2007). 
Cancer metastasis is a coordinated process that begins with detachment 
from the primary tumor, intravasation in vessels (blood or lymphatic), 
extravasation at a secondary site, and then growth at that secondary site. The 
underlying basis behind these differences in attachment and migration are 
changes to the cytoskeleton. There is a reorganization and differential expression 
of not only cytoskeletal proteins but also groups of regulatory proteins. 
Inherent in metastasis is the epithelial-mesenchymal transition (EMT). EMT is a 
reversible change in cell phenotype with a loss of cell-to-cell adhesive structures 
like adherens junctions and desmosomes and increased cell-to-matrix structures 
(Craene 2013). This can take place through downregulation of proteins like E-
cadherin, claudins, and occludins while there is an upregulation of N-cadherin, 
vimentin, and fibronectin, all contributing to the rearrangement of the 
cytoskeleton. There is also a change in cell shape to a fibroblastic morphology 
(Savagner 2010, Shanker 2010, Haynes 2011). 
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Electron microscopy has demonstrated a close interaction between the 
cytoskeleton and caveolae though the exact relationship is not yet understood 
(Breen 2012). Some caveolae have a near linear arrangement as tracks of 
cytoskeletal elements seemingly run through them suggesting a caveolae-
cystoskeletal interaction. Specifically, the intracellular transport ability of 
microtubules is necessary for trafficking of caveolin-1 to the membrane and for 
caveolae formation (Mundy 2002). Previous work in our lab has shown that in 
adipocytes, when caveolae are flattened by cholesterol depletion there is a loss of 
the cortical cytoskeleton (Breen 2012). Adipocytes though, have a drastically 
different cellular structure compared to epithelial cells so the applicability to all 
cell types is not yet known though data supports that this mechanism also takes 
place in fibroblasts (Breen 2012). 
1.4.2. · G TPase Signaling 
The Rho family guanine triphosphatases (GTPases) include RhoA (Ras 
homolog gene family member A), Racl (Ras-related C3 botulinum toxin 
substrate 1), and Cdc42 (cell division control protein 42 homolog). They are 
master regulators of signal transduction cascades that spatially and temporarily 
regulate cytoskeletal dynamics involved in cell motility, polarization, adhesion, 
and cytokinesis (Jaffe 2005). Rho family GTPases act as a binary switch when 
they hydrolyze GTP to GDP. The GTP bound form is the active form and is able 
to interact with its downstream effectors. When bound to GDP, they are unable 
to interact with partner proteins and are thus inactive. The GTPases themselves 
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have a weak GTP hydrolysis activity and are regulated by three different 
families: guanosine nucleotide dissociation inhibitors (GDis), guanosine 
nucleotide exchange factors (GEFs), and GTPase activating proteins (GAPs). 
GDis regulate GDP I GTP exchange by binding to the GDP bound form, 
sequestering the GTPase in its off state. GEFs activate the GTPase by increasing 
the rate of exchange of GDP for GTP. GAPs increase the weak innate hydrolysis 
of the GTPase to put the GTPase into the inactive state. To add to the complexity 
of the biology, over 70 RhoGEFs, 60 RhoGAPs and 3 RhoGDis have been 
identified (Vega 2008). 
The most commonly described function of the Rho protein family is as a 
connector between extracellular receptor signaling and organization of the 
cytoskeleton. The family controls actin in the formation of stress fibers, focal 
adhesions, membrane ruffling, lamelipodia, and filapodia (Ellenbroek 2007). The 
Rho family and in particular Cdc42 modulate cellular polarity by promoting 
microtubule stability. This allows cell migration to take place in a controlled 
directional manner. They also modulate the cells ability to interact with its 
surroundings by promoting the stabilization and disassembly of adherence 
structures like tight junctions, adherens junctions, and desmosomes. This in turn 
helps lead to EMT (Ellenbroek 2007). 
The Rho family of GTPases are frequently disrupted in tumorigenesis and 
metastasis and are described to be oncogenic. In breast cancer, colon, gastric, 
bladder, testicular, pancreatic, and lung tumors and metastasis, the activity of the 
Rho family is upregulated (Fritz 2002, Gomez Del Pulgar 2008, Fritz 1999, Jiang 
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2003, Ellenbroek 2007). Interestingly, very few mutational activations or 
inactivations have been discovered in cancers, which suggest changes in Rho 
family activity mostly stems from mutation of their regulators (Ellenbroek 2007). 
Upregulation of GTPases drives many of the hallmarks of cancer as they 
are regulators of angiogenesis, tumor cell invasion, and metastasis. In the highly 
metastatic MTLn3 breast cell line, transfection with a dominant negative RhoA 
and Cdc42 disrupts focal adhesion formation while transfection with the 
dominant negative isoforms RhoA, Racl, or Cdc42 inhibit migration. All were 
able to inhibit metastasis in mouse xenograft studies (Bouzahzah 2001). While 
mostly oncogenic, some studies have demonstrated a tumor suppressive role for 
GTPases in some cases. Cdc42 is upregulated in many cancers (Fritz 1999) 
however a liver specific knockout showed spontaneous hepatocarcinogenesis 
with lung metastasis (van Hengel2008) 
Previous studies have shown that Cav1 interacts with members of the 
RHO family, Cdc42 and RhoA (Nevins 2006 and Gingras 1998). Through sucrose 
gradient fractionation, they showed co-sedimentation of RhoA and CDC42 with 
caveolin-1. They also demonstrated direct binding through immunoprecipitation 
of RhoA and caveolin-1 (Gingras 1998). In the pancreatic beta cell line MIN6, 
Nevins et al was able to show with immunoprecipitation that caveolin-1 and 
Cdc42 interact. They also showed in MIN6 and CHO cells that caveolin-1 
preferentially binds to GDP bound Cdc42, suggesting that caveolin-1 may 
function as a GDI. Their hypothesis is bolstered by two pieces of data. First, 
alignment of caveolin-1 with known Rho and Rab GDI's shows a conserved 10 . 
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amino acid sequences. Secondly, knockdown of caveolin-1 results in a 
significant increase in Cdc42 activity as measured by the concentration of GTP 
bound Cdc42 (Nevins 2006). Others have described caveolin-1 to have a similar 
role. In mammalian sperm, caveolin-1 functions as a GDI, preventing Cdc42 
regulated exocytosis as a part of spermatic capacitation (Baltierrez-Hoyos 2010). 
Other GTPases have been examined. In adipocytes, caveolin-1 specifically binds 
GDP-bound and stabilizes GDP binding of the small GTPase TC10 (human 
teratocarcinoma protein 10)(Bridges 2012). In HeLa cells and in mouse 
embryonic fibroblasts caveolin-1 in a GDI capacity regulates the GTPase Racl in 
the context of directional migration. There are a few problems though with these 
results. Similar to other signaling pathways, a simple coimmunoprecipitation is 
not enough to ensure that the connection is real as coimmunoprecipitations of 
detergent resistant domains is fraught with potential artifacts. Secondly, 
previous research failed to examine the role of the cavin proteins (in part due to 
the predation of the discovery of cavin-1) with respect to the potential GDI 
function of caveolin-1. 
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2. Materials and Methods 
2.1. Antibodies 
Antibodies directed against caveolin-1, caveolin-2, and cdc42 were obtained from 
BD Transduction Laboratories (San Jose, CA). Anti-actin and anti-GAPDH 
antibodies were purchased from Sigma (St. Louis, MO). Antibodies recognizing 
cavin-1, cavin-2, and cavin-3 were generated by 21st Century Biochemicals 
(Marlboro, MA) as described (Bastiani 2009). Antibody to spectrin was acquired 
from Abeam (Cambridge, MA). Antibody directed against tubulin was 
purchased form Invitrogen (Grand Island, NY). Antibody to the estrogen 
receptor was obtained from Santa Cruz Biotechnology (Dallas, TX). The 
hemagglutinin (HA) antibody was purchased from Cell Signaling Technology 
(Danvers, MA). Antibody to cyclophilin was acquired from Millipore (Billerica, 
MA). 
2.2. Reagents 
The shRNA ~d siRNA constructs were purchased from Open Biosystems 
(Huntsville, AL). The shRNA target sequence to caveolin-1 was 
GACCCACTCTTTGAAGCTGTT and cavin-1 was 
GTGGAGGTTGAGGAGGTTATT. The siRNA for caveolin-1 and cavin-1 was 
purchased from Sigma and had an approximate start site of 442 and 1159 
respectively. The DharmaFECT transfection reagent was from Thermo 
(Waltham, MA), the TransiT-293 transfection reagent was from Mirus (Madison, 
WI), and the Lipofectamine 2000 was from Invitrogen. The inhibitors ML141 and 
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the ICI 182,780 were bought from Santa Cruz Biotechnology and simvastatin 
from Cayman Chemical (Ann Arbor, MI). 
2.3. Cell culture 
The MCF7, ZR75, MDA-MB-231, and HS578t cell lines were provided by Dr. Gail 
Sonenshein (Tufts University, MA). The highly metastatic MDA-MB-231 variant 
and MCF10a cell lines were provided by Dr. Bob Varelas (Boston University 
school of Medicine, MA). The M2, M3, and M4 cell lines were provided by Dr. 
Sam Thiagalingam (Boston University school of Medicine, MA). MCF10a cells 
were grown in Dulbecco's Modified Eagle Medium I Ham's F-12 (DMEMIF12) 
from Mediatech Inc (Herndon, VA) supplanted with 10% charcoal stripped horse 
serum (Invitrogen), 20nglml epidermal growth factor (EGF), .Smglml 
hydrocortisone, 10nglml cholera toxin, 10uglml insulin (Sigma, St. Louis, MO), 
100 unitslml penicillin, and 100uglml streptomycin (Invitrogen, NY). All other 
cell lines were grown in DMEM supplanted with 10% fetal bovine serum (FBS), 
100 units I ml penicillin, and 100 micrograms I milliliter streptomycin 
(Invitrogen). The phenol red free DMEM was purchased from Mediatech Inc. 
2.4. Lentiviril infection 
HEK293T cells were grown in DMEM supplanted with 10% fetal bovine serum, 
100 unitslml penicillin, and 100uglml streptomycin to 90% confluence in p100 
dishes and then trypsinized and plated onto p150 plates. Twenty-four hours 
after plating, cells were transfected with 24 micrograms I milliliter of shRN A, 1.2 
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micrograms Tat, 1.2 micrograms Rev, 1.2 micrograms Gag/pol, and 2.4 
micrograms vesiculostomatitis virus protein G. Two days after transfection, 
medium was collected and passed through a .45um filter with 8 
micrograms/milliliter polybrene onto the target breast cells at 40% confluence. 
One day after infection cells were selected with 2.5 micrograms I milliliter 
puromycin. Infected cells were maintained at 1 micrograms/milliliter 
puromycin. 
2.5. siRNA transfection 
6x105 MDA-MB-231 cells were added to p100 dishes. After 24 hours, the cells 
were transfected with 25 nanomolar siRNA directed against caveolin-1 and 
cavin-1 using DharmaFECT according to the manufacturers protocol. 
Knockdown efficiency was measured after 72 hours via western blot. 
2.6. Lipofectamine Transfection 
Cells were grown to 80% confluence and treated with a mixture of Lipofectamine 
2000 reagent and DNA according to manufacturers instruction. After 72 hours 
transfection levels were measured via western blot. 
2.7. Electroporation 
P100 were grown to confluence, trypsinized, and counted. 4x106cells and 10 
micrograms of plasmid DNA were added to the cuvettes in 800 microliters of 
serum free DMEM. Cuvettes were allowed to sit at 4 oc for five minutes before 
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electroporation was performed with 300 volts and 600 microfaradays. They were 
allowed to sit for ten minutes at room temperature and then plated in DMEM 
with 10%FBS. Efficiency was measure 72 hours after elecroporation via western 
blot. 
2.8. Preparation of whole celllysates 
Cells were washed twice in phosphate buffered saline (PBS: 3.2 mM N a2HP04, 
0.5 mM KH2P04, 1.3 millimolar KCl, and 135 millimolar NaCl) and incubated 
on ice for 30 minutes with cold RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 
1% Nonidet, .5% sodium deoxycholate, and .1% SDS) with a protease inhibitor 
cocktail (Aprotinin 10 microgram/ milliliter, Pepstatin 1 microgram/ milliliter, 
and Leupeptin 1 microgram/milliliter (American Bioanalyitical, Natick, MA)). 
Lysates were rocked end over end for 30 minutes at 4 °C and spun for 15 minutes 
at 16,000 times gravity at 4 oc. Supernatants were isolated and protein 
concentrations were measured using the BCA reagent assay (Pierce Rockford, 
IL). 
2.9. Western blotting 
Whole celllysates were added to Laemmli's sample buffer (LSB, 63mM Tris HCl, 
10% glycerol, 1% SDS .0025% bromophenol blue, pH 6.8) and boiled for 10 
minutes before being separated by SDS-PAGE (National Diagnostics, Atlanta, 
GA) gel electrophoresis as described by Laemmli (Cleveland 1977)~ They were 
then electrophoretically transferred to a polyvinylidene difluoride (PVDF) 
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membrane (Bio-Rad, Hercules, CA) in 25mM T:ris and 192 nanomolar glycine. 
After transfer, the PVDF membrane was blocked in 10% nonfat dry milk in PBS 
for 1 hour at room temperature. The membranes were incubated with the 
primary antibodies in PBST (PBS with .05% Tween 20) overnight at 4 oc. 
Horseradish peroxidase-conjugated secondary antibodies (Sigma) and an 
enhanced chemiluminescent substrate kit (Perkin-Elmer, Waltham, MA) and 
visualized by a Fuji LAS4000 image station. 
2.10. Colony growth assay 
2x103 cells were added to 35cm dishes. Media was replaced every two days. At 
10 days cells were stained with .005% crystal violet in 70% ethanol for an hour 
and washed three times with PBS. Plates were scanned and quantified using 
ImageJ. 
2.11. Wound Healing assay 
Cells were grown to confluence in 6 well dishes. The wound was made by 
scratching the monolayer with a 1-200ul pipette tip followed with three times 
washing with PBS. DMEM with 1% FBS was added. The wounds were 
photographed with Zeiss Axiovert 200 microscope using a 40x I 0.75 objectives 
and Axio Vision 4 software at 0, 24, and 48 hours. Wound size was quantified 
using ImageJ software and closure percentage was calculated with the formula: 
(area at time x -area at time O) I (area at time 0). 
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2.12. Transwell invasion 
Cells were serum starved for 4 hours prior to adding 1x10S cells in serum free 
DMEM to the upper well of a transwell invasion insert (8 uM pore size) that had 
been coated with matrigel (BD Biosciences). The lower chamber was filled with 
DMEM containing 10% FBS and the cells were cultured for 24 hours. To visualize 
cells, the transwell was placed in 0.5% crystal violet in 70% ethanol for an hour. 
The transwells were washed three times in PBS and imaged with a Zeiss 
Axiovert 200 microscope using a 40x/0.75 objectives and AxioVision 4 software. 
Images were quantified using ImageJ software 
2.13. Transwell migration 
2x104 cells in serum free DMEM were added to the upper well of cell cultur~ 
inserts (8 uM pore size) (BD Biosciences). Cells were allowed to migrate towards 
DMEM with 10% FBS. After 18 hours the inserts were stained with .5% crystal 
violet in 70% ethanol for an hour and washed four times with PBS. Membranes 
were photographed with Zeiss Axiovert 200 microscope using a 40x I 0.75 
objectives and AxioVision 4 software and quantified cell counting. 
2.14. Immunofluorescence 
5x104 cells were plated into 6 well plates containing coverslips coated with .1% 
gelatin. The next day cells were fixed with 4% paraformaldehyde in PBS for 15 
minutes at room temperature while rocking. Cells were permeabilized with 
solution A (.1% saponin (Sigma) and .4% bovine serum albumin in PBS) for 10 
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minutes then blocked for 1 hour at room temperature in 5% normal goat serum 
(Sigma) in PBS. Staining was done with TRITC (tetramethyl-isothiocyanate)-
phalloidin overnight at 4 oc at a 1 I 400 dilution. Coverslips were then washed 
with solution A 3 times and mounted with Vectashield mounting medium with 
DAPI (diamidino-2-phenylindole) (Vector Laboratories, Burlingame, CA). The 
slides were visualized with the Zeiss immunofluorescent microscope Axio 
Observer Zl. 
2.15. Cdc42 activity 
Protein was isolated by RIP A lysis as described above. CST (glutathione S-
transferase) or Pak1-GST (p21-activated kinase 1) was combined with equal 
amounts of cell lysate at 20 microgram per milligram of lysate for 2 hours at 4 oc. 
That mixture was added to washed glutathione bead for 1 hour at 4 oc. The 
supernatant was removed and the beads were washed three times in PBS before 
being boiled. The bound fraction was removed and subjected to western blot 
analysis. 
2.16. Zymography 
Cells were serum·starved for 4 hours before media was collected and 
concentrated with Centricon YM-100 centrifugal devices (Millipore). Equal 
amounts of media were loaded onto a 10% zymogram gel (Invitrogen). After 
electrophoretic separation, gels were incubated according to manufacturers 
instruction in renaturing buffer for 30 minutes and developing buffer overnight. 
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The gels were stained in 0.25% Coomassie Brilliant Blue R-250 (50% methanol, 
10% acetic acid, 40% water) and destained in 20% methanol, 10% acetic acid, 70% 
water. The gels were visualized with a Fuji LAS4000 image station. 
2.17. Statistical analysis 
Results are expressed as+ I- standard error of the mean (SEM). Student's t-test 
was used to analyze differences with p<O.OS being considered significant. 
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3. Results 
3.1. Expression of Caveolin and Cavin Family of Proteins in Breast Cancer 
Caveolin-1 has had a place in caveolae and cancer research for decades, 
however most of this research in both fields has been done without knowledge of 
the cavin proteins. The recent discovery of the cavins has stressed their 
importance for proper caveolae formation and function while calling into 
question the conclusions drawn from many studies. I hypothesize that the 
cavins, in particular cavin-1, together with caveolin-1 contributes to both the 
aggressiveness of breast cancer and its further study will shed light on the 
confusion behind the dichotomous role of caveolin-1. To test this I began by 
exploring the expression of the cavin family of proteins in breast cancer. 
3.1.a. The Cavin Proteins are Decreased in Ductal Breast Carcinomas. 
The majority of breast cancer cases are ductal carcinomas making a greater 
understanding of their specific molecular pathology a priority in breast cancer 
research. Previous research into caveolin-1 has generally demonstrated that it is 
decreased in breast cancer however because it is seen as both a tumor suppressor 
and an oncogene I began my exploration into the cavin proteins by looking at 
their expression status in human carcinomas. To begin our pursuit into cavin-1, I 
wanted to know if there is a clinical importance in humans as well as to gain a 
greater understanding of cavin-1 expression. Oncomine.org is a cancer 
microarray database that allows for web based data mining and would let us 
achieve both goals at once. Focusing on breast ductal carcinoma, Oncomine.org 
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shows that mRNA expression of cavin-1 and cavin-2 are significantly reduced in 
cancer when compared to patient matched normal breast tissue in the majority of 
studies available. Cavin-3 however showed no significant change in cancer 
tissue when compared to normal (Figure 4A). A representative study shown 
demonstrates the difference in expression is not only significant but substantial 
as cavin-1 expression is all but absent when compared to the normal tissue 
(Figure 4b). I was encouraged by these results as they supported a role for cavin-
1 in breast cancer. 
3.1.b. The Caveolin and Cavin Proteins in Breast Cancer Cell Lines. 
While the human data derived from Oncomine advocated for our 
hypothesis, it measured mRNA and not protein, the important player in caveolae 
formation so I decided to focus out efforts on cancer cell lines, a system more 
easily manipulated and studied in vitro. I first examined endogenous protein 
expression of caveolin and cavin family members via western blot in 4 human 
breast cancer cell lines and 1 immortalized breast cell line with the goal of 
characterizing the different cell lines (Figure 5). The MCF10a line is an 
immortalized breast cell line and served as our non-tumorigenic control. MDA-
MB-231 and HS678t are ER negative cell lines that are basal in origin while the 
MCF7 and ZR75 are ER positive cell lines that are luminal in origin, all of which 
are described in detail in Neve et al2006. First, I saw that in general the caveolin 
and cavin family expression follows the human breast cancer mRNA data in that 
they are generally decreased. Cavin-1 and caveolin-1 are decreased 
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Figure 4. Cavin proteins are decreased in human ductal breast carcinomas. 
Using the online database Oncomine (Oncomine.org), mRNA of cavin 1-3 
expression was measured in ductal breast carcinomas. (A) A graphical 
representation of all studies that measured cavin proteins in normal tissue, 
carcinoma in situ, and invasive carcinomas. (B) A representative study 
comparing cavin-1 mRNA levels in normal breast tissue to ductal breast 
carcinoma. 
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Figure 5. Expression of caveolin and cavin proteins in breast cancer cell lines. 
The immortalized breast line MCFlOa and four breast cancer cell lines were 
grown to near confluence. Whole celllysates were prepared as described in the 
materials and methods before being subjected to SDS-PAGE and western blot 
analysis to measure the proteins indicated. Cyclophilin levels were used as a 
loading control. Data shown are representative of greater than three 
independent experiments. 
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in all cancer cell lines compared to the immortalized line suggesting a tumor 
suppressive role for the proteins. I also saw that there is an inverse relationship 
between the cavin and caveolin family when compared to the estrogen receptor. 
The MCF7 and ZR75 ER positive lines have no visible caveolin or cavin 
expression while these proteins can be detected in the three ER negative cell 
lines. Together these observations suggested that the human breast cancer cell 
lines are a useful model to study the role of the cavin protein family in cancer as 
well as a possible mechanism behind the observed changes. 
3.l.c. Expression of the Estrogen Receptor Does Not Increase Protein 
Expression of Caveolin or Cavin Proteins. 
I postulated that the observed inverse expression of ER and caveolar 
proteins was due to a functional relationship where either estrogen signaling is 
able to suppress caveolin and cavin or that caveolae are suppressing the ER. To 
test the relationship, I expressed ERin the normally ER null HS578t cell line and 
measured protein expression of caveolin-1 and cavin-1. I saw no change in gross 
protein levels suggesting that simple ER status does not directly regulate 
caveolar protein levels (Figure 6). However this does not preclude the possibility 
of other methods of regulation between caveolae and ER. 
To further examine the connection between ER and caveolae, I examined 
estrogen signaling in ER positive cells. To do this, I treated MCF7 and ZR75 cells 
with the compound ICI 182780 in phenol red free DMEM in order to block 
estrogen signaling. ICI 182780 is a high affinity estrogen receptor antagonist and 
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Figure 6. Estrogen receptor expression in estrogen receptor negative cell lines 
does not affect expression of caveolin and cavin proteins. 
Cells were grown to sixty percent confluence before being transfected with an ER 
plasmid (marked as"+") via Lipofectamine 2000 per manufacturers instructions. 
72 hours post transfection, whole celllysates were prepared in RIP A buffer 
before being subjected to SDS-PAGE and western blot analysis in order to 
measure the proteins indicated. Actin levels were used as a loading control. Data 
shown are representative of three experiments. 
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phenol red free media was used because this component of DMEM is a weak 
estrogen mimetic (Howell 2000). After a week of treatment I measured gross 
caveolin-1 and cavin-1 protein expression and found no difference between the 
untreated control cells (Figure 7). This led us to believe that neither ER levels nor 
estrogen signaling modifies caveolin-1 or cavin-1 expression. 
As I saw no changes with forced expression of ER or inhibition of ER, I 
hypothesized that caveolae could be regulating ER expression. To test this I 
made stable caveolin-1, cavin-1, and a dual caveolin-1 I cavin-1 expressing MCF7 
cell lines. This however had no effect on ER (Figure 8). Together, the data 
suggest that the inverse relationship seen in the breast cancer cell lines is not due 
to a directly functional relationship between caveolae and ER. 
3.2. The Role of Caveolin-1 and Cavin-1 in Tumorigenesis 
In both cell lines and human carcinomas, I see a decrease in the expression 
of the cavin family of proteins that is independent from estrogen function. This 
supported our original hypothesis that the cavins are involved in breast cancer 
progression and led us to inspect the specific changes in cellular function 
brought about differences in cavin expression. 
3.2.a. Knockdown of Caveolin or Cavin Proteins Reduces Caveolar Protein 
Expression 
In order to explore the different aspects of tumorigenesis and the 
hallmarks of cancer, I first knocked down caveolin-1 and cavin-1 in MDA-MB-
60 
Figure 7. Estrogen receptor signaling does not change caveolin-1 or cavin-1 
expression in estrogen receptor positive breast cell lines. 
Equal numbers of MCF7 and ZR75 breast cancer cells were plated and grown for 
seven days in phenol red free media. Cells were treated with the anti-estrogen 
ICI 182780 at 1 micromolar. At the end of seven days, whole celllysates were 
and subjected to SDS-PAGE and western blot analysis in order to measure the 
proteins indicated. Actin levels were used as a loading control. Data shown are 
representative of three independent experiments. 
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Figure 8. Caveolin-1 and cavin-1 expression does not change estrogen receptor 
protein expression levels in estrogen receptor positive breast cancer cell lines. 
Caveolin-1 and I or cavin-1 plasmids were electroporated into MCF7 cells as 
described in the material and methods. Whole celllysates were prepared in 
RIPA buffer before being subjected to SDS-PAGE and western blot analysis in 
order to measure the proteins indicated. Actin levels were used as a loading 
control. Data shown are representative of three experiments 
63 
Caveolin-1 
~=============: 
HA-Cavin-1 
::::::================: 
Cavin-2 
Cavin-3 
ER 
Actin 
64 
231 and HS578t cells with shRNA (Figure 9a) and siRNA (Figure 9b). These cell 
lines were chosen because of their robust caveolin protein expression. When I 
targeted caveolin-1, I showed a decrease in both caveolin-1 and cavin-1 as well. 
Similarly, when I targeted cavin-1, both caveolin-1 and cavin-1 were decreased. 
This was an expected result and supports the current understand of caveolae, in 
that both proteins are required for caveolae formation and that depletion of 
cavin-1 results in diffusion of caveolin-1 from caveolae (Liu 2008, Hill2008). 
Also, as described in the knockout mice, loss of either protein results in 
decreased expression of the other (Liu 2008). 
I wanted to manipulate caveolae in ways other than at the level of RNA. 
If pharmacological routes are effective at inhibiting tumorigenesis, it could 
possibly make the results more clinically relevant. Because cholesterol depletion 
is effective at disrupting caveolae and causing a degradation of cavin proteins in 
adipocytes and fibroblasts, I wanted to cpnfirm that depletion is also effective in 
breast cancer cells. Low dose statin treatment is effective at reducing cavin and 
caveolin protein levels after twenty-four hours in MDA-MB-231 and HS578t cell 
lines (Figure lOA and lOB). 
3.2.b. Knockdown of Caveolin or Cavin Proteins Increases Proliferation in the 
HS578t Breast Cancer Cell Line. 
Excess proliferation is a critical change for cancer progression and is often 
effected by tumor suppressors and oncogenes. It was shown that expression of 
caveolin-1 in the breast cell lines MCF7 and T47D results in a decrease in their 
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Figure 9. Knock-down of caveolin-1 and cavin-1 in breast cancer cell lines. 
(A) Lentiviral vectors with shRNA directed to caveolin-1 and cavin-1 were made 
in HEK cells as described in the Materials and Methods and used to infect and 
knock-down the target proteins in the breast cancer cell lines HS578t and MDA-
MB-231. After 48 hours knock-down cell were selected for. Cells were grown to 
confluence and whole celllysates were prepared in RIP A buffer before being 
subjected to SDS-PAGE and western blot analysis in order to measure the 
proteins indicated. Actin levels were used as a loading control. Shown is a 
representative image of greater than three experiments. (B) Caveolin-1 and 
cavin-1 siRNA vectors were transiently transfeded withDharmaFECT as 
described in the materials and methods into HS578t and MDA-MB-231 cell lines., 
Whole celllysates were prepared in RIP A buffer 72 hours after transfection 
before being subjected to SDS-PAGE and western blot analysis in order to 
measure the proteins indicated. Actin and spectrin levels were used as a loading 
control. Shown is a representative image of 3 experiments. 
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Figure 10: Cholesterol depletion in breast cancer cell lines decrease caveolin-1 
and cavin-1 protein levels. 
(A) MDA-MB-231 and (B) HS578t cell lines were grown to sixty percent 
confluence and treated with simvastatin to inhibit cholesterol biosynthesis (doses 
indicated are in micromolar). At the indicated time periods, whole celllysates 
were prepared in RIPA buffer before being subjected to SDS-PAGE and western 
blot analysis in order to measure the proteins indicated. Tubulin levels were 
used as a loading control. Shown is a representative image of greater than three 
independent experiments. 
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growth rate which caused us to question the role of cavin-1 in this process (Fiucci 
2002 and Lee 1998). To explore further, the caveolin-1 and cavin-1 knockdown in 
MDA-MB-231 and HS578t cells were plated at very low density and allowed to 
grow for 10 days before being stained and quantified (Figure llA and llB). 
Quantification of the HS578t colonies shows that knockdown of either protein 
results in a statistically significant increase in total staining and colony size 
suggesting a decreased rate of proliferation (Figure 11C). 
3.2.c. Knockdown of Caveolin-1 or Cavin-1 Increases Migration in MDA-MB-
231 and HS578t Cell Lines. 
An important aspect of tumorigenesis that caveolin-1 has been implicated 
in is tumor cell motility (Goetz 1998). I looked at the role of cavin-1 in migration 
by performing scratch wound healing assays. In short, cells were grown to 
confluence before a row of cells was scratched off with a pipette tip creating a 
wound that was free of cells in the once confluent monolayer. Cells at the edge 
of the wound will then migrate into the open space without proliferation due to 
the low serum condition. I see at 48 hours after wound creation, the wildtype 
MDA-MB-231 (Figure 12A) and HS578t (Figure 12B) cells partially migrate into 
the wound while the knockdown cells demonstrate an increase in migratory 
capability by fully filling the available space. This supports the hypothesis that 
cavin-1 may function as a tumor suppressor in breast cancer cell lines. 
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Figure 11: Knockdown of caveolin-1 and caviri-1 increases the rate and size of 
colony growth. 
2x103 (A) MDA-MB-231 and (B) HS578t cells were plated and allowed to grow 
for 10 days as described in the materials and methods. At the end of the time 
period, cells were fixed and stained with .005% crystal violet in 70% ethanol in 
order to visually monitor relative proliferation rates. Shown are representative 
images of three independent experiments. (C) Fixed and stained HS578t cells 
were scanned and quantified using ImageJ software. The graph shows the 
percentage of the plate that is stained; *p<.05. 
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Figure 12: Depletion of cavin-1 causes an increased rate of wound healing. 
An equal number of wild type and cavin-1 knockdown (A) MDA-MB-231 and (B) 
Hs578t cells were plated. When at confluence, a wound was scratched in the 
monolayers and the cells were allowed to grow in DMEM with 1% FBS for up to 
48 hours as described in the materials and methods. Images were taken at 0, 24, 
and 48 hours post wounding with a Zeiss Axiovert 200 microscope. Shown are 
representative images of over three independent experiments. Graphs shown are 
the percent of wound closure +I -SEM after 48 hours; *p<.05. 
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3.2.d. Knockdown of Caveolin-1 or Cavin-1 Increases Transwell Invasion and 
MMP Activity in MDA-MB-231 Cell Lines. 
Having seen changes in multiple of the hallmarks of cancer, I next explored 
caveolae's relationship with invasiveness. Caveolae have been connected to 
invasion and metastasis formation previously as it has been shown in MCF7 cells 
that overexpression of caveolin-1 will decrease invasion. In order for metastatic 
cells to intravasate into the blood stream, they must first break through the 
barrier of the basement membrane. The main protein component of this barrier 
is type IV collagen. The transwell assay mimics the 
process of invasion by simulating the basement membrane with a gelatinous 
protein mixture rich in type IV collagen extracted from the Engelbreth-Holm-
Swarm mouse sarcoma cell line (Kibbey 1994). Using a transwell coated in. 
matrigel, MDA-MB-231 cells were allowed to migration towards a 
chemoattractant for 24 hours. Cells that were able to break through the matrigel 
layer adhered to the base of the transwell and were counted towards total 
invasion. I see that knockdown of caveolin-1 or cavin-1 in the MDA-MB-231 
increases the total invasiveness of the cells (Figure 13A). 
Matrix metalloproteinases (MMPs) are proteases involved in the 
degradation of many extracellular matrix proteins and play in important role in 
many physiological and pathological processes including the different hallmarks 
of cancer. Specifically, the gelatinases MMP2 and MMP9 are often examined in 
the context of cancer metastasis because their main substrates are type IV 
collagen and gelatin. The enzymatic activity of MMPs can be measured with 
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Figure 13: Knockdown of caveolin-1 and cavin-1 results in increased invasion 
and MMP activity 
A) Using the MDA-M-231 knock"'down cell lines, 2x105 cells were added to the 
upper chamber of the transwell in serum free DMEM and allowed to migrate to 
towards DMEM with 10% FBS for 24 hours as described in the material and 
methods. After invasion, transwells were fixed and stained with 0.5% crystal 
violet in 70% ethanol for an hour. Transwells were washed in PBS before being 
imaged with a Zeiss Axiovert 200 microscope. Total invasion was measured by 
total staining intensity using ImageJ software. Graphs shown are the staining 
intensity+ I -SEM after 24 hours; *p<.05 .. B) Cells were grown to confluence and 
then placed in serum free media for 4 hours. Media samples were collected and 
concentrated before electrophoretic separation on a 10% zymogram gel. Gels 
were renatured and developed according to manufacturers instruction before 
staining with 0.25% Coomassie Brilliant Blue R-250 and visualized with a Fuji 
LAS4000 image station. Graphs shown are the relative MMP activity +I -SEM; 
*p<.05. Shown are representative images of over three independent experiments. 
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zymography. Similar to SDS-PAGE, media from cells is run on a gel containing 
the appropriate substrate and placed in buffer appropriate to allow MMP 
enzymatic activity. The gels can be stained and areas of digestion can be 
observed as clear bands against a dark, stained background. I show that there is 
an increase in MMP-2 activity in the media from cells where caveolin-1 and 
cavin-1 have been knocked down (Figure 13B). Together these data support that 
caveolin-1 and cavin-1 function as tumor suppressors in breast cancer as loss of 
them generally increases the aggressiveness of the cells in tissue culture. 
3.2.e. Cholesterol Depletion Inhibits Invasion in MDA-MB-231 Cell Line. 
Having shown that I can manipulate caveolin and cavin levels with statin 
treatment, I wanted to see if it would also produce an effect on invasion similar 
to knockdown through shRNA. I treated wildtype MD-MB-231 cells with statin 
doses that robustly depleted the cavin proteins and allowed them to invade for 
twenty-four hours in a transwell with a matrigel coating. I see that statin 
treatment causes a dose dependant reduction in invasion (Figure 14A-D). These 
results are in contrast to our previous invasion data from the knockdown cell 
lines and suggest that cholesterols effect on invasion may not be related to the 
loss of caveolae. 
3.2.£. Caveolin and Cavin Protein Families are Downregulated in Highly 
Metastatic Breast Cancer Cells and Decrease During Tumor Progression. 
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Figure 14: Cholesterol depletion in MDA-MB-231 inhibits invasion. 
MDA-MB-231 cells were grown to confluence then trypsinized and counted. 5e4 
cells were added to the upper chamber of the transwell in serum free DMEM and 
allowed to migrate to towards DMEM with 10% FBS for 24 hours. At the start in 
invasion, cells were treated with (A) vehicle, (B) 5 micromolar, or (C) 10 
micromolar of simvastastin. Shown are representative images of three 
experiments. After invasion, transwells were fixed and stained with 0.5% crystal 
violet in 70% ethanol for an hour. Transwells were washed in PBS before being 
imaged with a Zeiss Axiovert 200 microscope. Total invasion was measured by 
cell counting. (D) Graphs shown are the percent invasion to the vehicle treated 
cells +I -SEM after 24 hours; *p<.OS. 
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While caveolin-1 has been described to both inhibit and encourage 
metastasis in different cancers, our data so far suggest that in breast cancer, both 
caveolin-1 and cavin-1 inhibit metastasis as measured by our invasion assays. To 
further this thought, I measured via western blot, caveolar protein expression in 
a highly metastatic variant of the MDA-MB-231 breast cell line. Briefly, this cell 
.line was produced by isolating and selecting metastatic lung nodules after hind 
flank injection of wildtype MDA-MB-231 cells (Munoz 2006). This experiment 
differs from previous data in that the difference between the experimental line 
and the control is not due to exogenous manipulation of proteins levels, but from 
growth in vivo and evolution into a metastatic variant. I show that caveolar 
protein expression is decreased in the highly metastic variant compared to 
wildtype MDA-MB-231 (Figure 15). 
Together, it suggests that caveolin-1 and cavin-1 have an active role in tumor 
suppression and play an important part in cancer progression. 
To further explore the changes in caveolin and cavin protein expression 
during tumorigenesis, I measured via western blot the protein expression in 
MCF10a variant cells (Figure 16). When these cell lines are injected into nude 
mice they have different growth and metastases rate and thus represent different 
stages of cancer (Miller 2000). The M1 cell line is the immortalized MCF10a line 
and in nontumorigenic. The M2 cell line represents premalignant epithelium 
and was made by transfection of the H-RAS oncogene (transforming protein 
p21). The M3 and M4 cell lines are malignant carcinomas that were derived from 
M2 cell carcinomas in mice (Miller 2000). I see a reduction in the caveolin and 
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Figure 15: Caveolin-1 and cavin-1 is decreased in highly metastatic MDA-MB-
231 cells. 
Wildtype MDA-MB-231 cells and a highly metastatic variant (described in 
Munoz 2006) were grown to confluence. Whole celllysates were prepared before 
being subjected to SDS-PAGE and western blot analysis to measure the proteins 
indicated. Actin and spectrin levels were used as a loading control. Data shown 
are representative of greater than three independent experiments. 
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Figure 16: Caveolin and cavin proteins decrease in more aggressive MCFlOA 
cells. 
MCFlOA variant cells were grown to confluence. Ml (not shown) is wildtype 
MCFlOA and M2 is stably transfected with H-Ras. M3 and M4 were derived 
from M2 after in vivo passage and represent low metastatic and high metastatic 
potential respectively. Whole celllysates were prepared before being subjected 
to SDS-PAGE and western blot analysis to measure the proteins indicated. Actin 
levels were used as a loading control. Data shown are representative of two 
independent experiments. 
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cavin family of proteins as the various cell lines increase in aggressiveness 
supporting the results seen in the highly metastatic MDA-MB-231 cells. 
3.2.g. No Difference Seen in the Actin Cytoskeleton After Depletion of 
Caveolin-1 and Cavin-1. 
I clearly saw differences in tumorigenic properties of our cells after 
knockdown of caveolin-1 and cavin-1, however I still did not understand how 
manipulating these domains at the plasma membrane has such a global cellular 
effect. I set out to examine likely mechanisms beginning with global cytoskeletal 
changes. I chose this as a starting point because previous work from our lab in 
adipocytes supported a collapse of the cortical cytoskeleton after cavin-2 
knockdown and cholesterol depletion. This was also a likely mechanism because 
caveolae were described to be a membrane reservoir that may be important as 
metastatic cells travel through the body even though I see low cavins in 
metastastic cells. Following our work in adipocytes, I used phalloidin staining to 
examine actin organization via immunofluorescence (Figure 17). I see no 
differences in actin organization after knockdown of caveolin-1 or cavin-1. This 
does not necessarily rule out cytoskeletal involvement as a mechanism as the 
cytoarchitecture includes elements not involved in motility. 
3.2.h. Signaling Differences in the MDA-MB-231 Cell Line After Depletion of 
Caveolin-1 and Cavin-1. 
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Figure 17: Depletion of caveolin-1 and cavin-1 produces no observable change 
in the actin cytoskeleton in MDA-MB-231 cells. 
MDA-MB-231 cells were grown to confluence, trypsinized, and counted. 5e4 
cells were plated onto coverslips pre coated with .1% gelatin. After 24 hours cells 
were fixed in 4% paraformaldehyde, permeabilized with solution A, and stained 
with phalloidin overnight. Coverslips were mounted and visualized with an 
Axio Observer Z1 microscope. Shown are representative images of over thirty 
examined cells. 
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I next investigated whether loss of caveolar proteins led to a change in cell 
signaling. Active Cdc42 is important for cell polarization, migration, and 
cytoskeletal organization in many different cell types. In cancer, the Rho family 
GTPases are frequently upregulated and involvement has been described in most 
aspects of tumorigenesis (Sahai 2002). Caveolin-1 has been implicated as a 
potential GDI marking caveolin-1 and an important regulator of Cdc42 activity. I 
measured the amount of active Cdc42 present in MDA-MB-231 cells and were 
able to show that depletion of caveolin-1 and cavin-1 led to an increase in the 
total amount active Cdc42 (Figure 18). This suggests that disruption of the 
caveolar proteins leads to decreased regulation of Cdc42 signaling and a 
subsequent increase in the aggressiveness of the cancer cells. 
3.2.i Inhibition of Cdc42 Activity Abrogates the Increase in Migration Seen 
With Knockdown of Caveolin-1 and Cavin-1. 
To show that Cdc42 is a driver of the observed phenotypic changes, 
inhibition of Cdc42 should abrogate the increase in tumorigenic properties seen 
after knockdown of caveolin-1 or cavin-1. To test this I used ML141, a potent, 
selective, and reversible non-competitive inhibitor of the Cdc42 GTPase with low 
micromolar activity (Surviladze 2010). Wildtype and knockdown cells were 
subjected to a transwell migration assay. The assay is similar to the transwell 
assay used for invasion however there is no matrigel barrier .preventing 
migration. As expected, knockdown of caveolin-1 and cavin-1 results in an 
increase in migratory capacity but when treated with ML141 the increase is lost 
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Figure 18: Active Cdc42 increases after depletion of caveolin-1 and cavin-1. 
Whole cell lysate was prepared from confluent MDA-MB-231 cells. GST and 
Pakl-GST proteins were incubated with equal amounts of the whole cell lysate as 
described in the materials and methods. The Pakl protein selectively binds 
Cdc42-GTP allowing us to isolate the active Cdc42 by binding the GST with 
glutathione beads. Beads were boiled to remove the protein and subjected to 
SDS-PAGE and western blot analysis to measure the proteins indicated. Graphs 
. shown are the percent change to GTP-Cdc42 +I -SEM; *p<.05. 
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as migration is similar to wildtype levels (Figure 19). Together this suggested 
that Cdc42 is at least partially responsible for the pathologic changes seen with 
caveolin-1 and cavin-1 disruption. 
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Figure 19: Inhibition of Cdc42 activity abrogates the increase in migration 
seen with knockdown of caveolin-1 and cavin-1. 
A) Using the MDA-M-231 knock-down cell lines, 2e4 cells were added to the 
upper chamber of the transwell in serum free DMEM and allowed to migrate to 
towards DMEM with 10% FBS for 24 hours as described in the material and 
methods. At time 0, 5 micromolars of ML141 or vehicle was added to the upper 
chamber. After migration, transwells were fixed and stained with 0.5% crystal 
violet in 70% ethanol for an hour. Transwells were washed in PBS before being 
imaged with a Zeiss Axiovert 200 microscope. Total mgiration was measured by 
cell counting. Shown are representative images from three independent 
experiments. Graphs shown are the percent changes in migration after 18 hours 
+I -SEM after 24 hours; *p<.05. 
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4. Discussion 
4.1. Summary of Results. 
In this study I looked at the form and function of caveolae, specifically the 
cavin-1 protein in breast cancer behavior in vitro. Caveolae are composed of two 
families of the proteins, the caveolins and the cavins. The caveolins have been 
studied for decades while the cavins have only been recently shown to be critical 
to caveolae formation. In cancer, caveolin-1 has been shown to both positively 
and negatively influence cancer progression. Very little research has been done 
on the cavin family and even less on cavins in cancer so I attempted to shed light 
on the duel nature that has been seen of caveolae in the context of cancer by 
focusing on the role of cavin-1 in breast cancer. 
I began by looking at the expression of the cavin family of proteins both in 
human breast tissue and breast cancer cell lines. In both I see that there is a 
general decrease in expression, supporting our hypothesis. Also of note is the 
observation that there is an inverse expression of caveolins and cavins compared 
to estrogen receptor. This observation was first shown in 2006 (Neve 2006) but 
just with the caveolins, and the cavins were not examined at that time. I 
explored this as a likely mechanistic explanation for the observed differences. 
However this did not prove to be the case as changes in ER signaling as well as 
ER expression had no effect on caveolin or cavin expression. Forced expression 
of caveolin and/ or cavin in turn had no effect on ER protein expression. These 
data forced us to dismiss the hypothesis that ER signaling is a mechanism for the 
differences in protein levels but that will be discussed in detail in a later section. 
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While the hypothesis that the ER are involved with caveolae was not 
supported, I still wanted to better understand the function of cavin-1 in breast 
cancer. After determining the best way to manipulate caveolin-1 and cavin-1 
levels in breast cancer cell lines, I used a variety of techniques to examine 
potential changes in the in vitro behavioral characteristics of cancer cells. I see 
that knockdown of both caveolin-1 and cavin-1leads to increases in proliferation, 
migration, and invasion as well as increased MMP activity, all suggesting a 
tumor suppressive role for caveolin-1 and cavin-1. If cavin proteins are indeed 
tumor suppressors, I would expect them to be decreased in metastases. I used a 
highly metastatic variant of MDA-MB-231 to compare caveolar protein 
expression to wildtype MDA-MB-231. They show near complete loss of the 
cavin proteins. I also see in MCF10a variant cell lines that differ based on 
tumorigenicity in nude mice, a gradual decrease in caveolin and cavin expression 
as tumorigenicity increases. This supports the tumor suppressive role as well as 
demonstrating that the differences I observed are not due to our exogenous 
manipulation of protein levels as the highly metastatic variant was made 
through selection in the mouse and thus all changes are endogenous. 
I next set out to determine a mechanism behind our observations. The 
two main hypotheses that I pursued involved the cytoskeleton and cellular 
signaling. To examine the cytoskeleton I looked at actin staining via 
immunofluorescence however I see no difference between our knockdown and 
wildtype cells. While our techniques were not able to determine a difference in 
expression or organization of the cytoskeleton after caveolin-1 or cavin-1 
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manipulation, it does not rule out the possibility of an intimate connection 
between caveolae and the cytoskeleton in breast cancer. Further research into 
this hypothesis should also take care to examine the possible role of other 
cytoskeletal elements like the intermediate filaments and the microtubules. The 
other avenue of research was into changes in cell signaling. I examined Rho 
family GTPase signaling because caveolin-1 has previously been shown to be a 
GDI and regulate Rho family signaling through inhibitory binding. I show that 
knockdown of caveolin-1 agrees with previous results in that it increases Cdc42 
activity but I also uniquely show that cavin-1 knockdown also is able to increase 
Cdc42 activity. To confirm that the Rho family GTPase, Cdc42, is the driver of 
our phenotypic changes, I inhibited Cdc42 activity with a small molecule 
inhibitor. When treated with the Cdc42 inhibitor, I see the migratory capability 
of the cells decrease back to wildtype levels, supporting a mechanistic role for 
Cdc42 in caveolae function. I see that that disruption of caveolae leads to a 
change in cellular signaling, specifically Cdc42, which in turn leads to the 
observed changes in tumorigenesis. 
4.2. The Estrogen Receptor/Caveolae Relationship 
One of our first hypotheses was that caveolae were functionally connected 
to the estrogen receptor and its signaling. I was excited at this prospect for a few 
reasons. First, classical (nuclear) estrogen signaling involves the hormone 
binding to the receptor in the cytoplasm, nuclear translocation, dimerization, and 
subsequent binding to hormone responsive elements in the DNA where 
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transcription is influenced. Some groups have described a non-classical, or 
function estrogen receptor at the plasma membrane (PM-ER). The PM-ER, which 
makes up 5-10% of the cellular ER, has been shown to explain rapid responses to 
estrogen that are believed to be through G protein coupled receptor activation of 
kinase pathways (Levin 2009, Levin 2010). While many studies have shown the 
importance of caveolae' s involvement in signaling pathways, some may not be 
true due to the reliance on detergent resistant membranes in early work to isolate 
caveolae. It is not widely accepted but is has been shown the PM-ER binds 
caveolin-1, and is localized near caveolar domains (Razandi 2003). Because 
estrogen signaling is such a critical driver of ER positive tumors and is a 
druggable target in patient care, a functional connection between ER and 
caveolae was an exciting hypothesis. Secondly, the inverse relationship between 
caveolin-1 and ER as shown in the 2006 Cancer Cell paper from Neve et al, 
suggests that there could some form of negative regulation. Lastly, the ER 
signaling is a driver of growth in ER positive cancers, yet is a highly druggable 
target during treatment. If a functional connection between caveolin-1 and ER it 
lends credibility to the idea that caveolae could also one day become a clinically 
relevant drug target. Our results though do not support this hypothesis as I 
showed that 1) treatment with the estrogen receptor antagonist ICI-182780 for 
upwards of 10 days had no effect on caveolar protein expression in ER+ cells, 2) 
transfection of ER into ER- cell lines had no effect on caveolar protein expression, 
and 3) transfection of Cav1 or cavin-1 into the caveolar null ER+ cells results in 
no change in ER + protein levels. 
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After the rejection of our initial hypothesis, I was still interested in the 
mechanism behind the observed inverse relationship seen in the literature and in 
our data. The 2006 cancer cell paper details nearly 50 breast cancer cell lines, 
which is where the inverse relationship between caveolin-1 and ER was first 
observed. I also observed that the majority of the ER positive cells are luminal in 
origin where as the majority of the ER negative cells are basal in origin. Some 
studies have looked at caveolin expression in normal breast tissue and showed 
that the ER positive luminal cells are caveolin null while the ER negative 
myoepithelial/basal cells are caveolin positive (Savage 2007, Savage 2008, Li 
2010). With our negative data towards a functional relationship, I find that the 
different cell of origin explanation goes a long way to explain our observations. 
This does not preclude a role for caveolin-1 or cavin-1 in breast cancer 
progression and under this new paradigm I attempted to determine the cavins 
role in breast cancer. 
4.3. The Necessity of Caveolin-1 and Cavin-1 
As observed in figure 8, when I knockdown either caveolin-1 or cavin-1, I 
see a decrease in both proteins. I also see in figure 6 that when I deplete caveolae 
through cholesterol depletion I see a loss of the caveolins and cavins. This result 
fits with previous results in that when caveolin-1 is knocked down or knocked 
out, there is a respective loss of cavin-1. In cavin-1 knockdown cells and 
knockout mice there is also a loss of caveolin-1. 
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When I look at the functional cellular differences in the knockdown breast 
cells, I see similar results between the caveolin-1 and the cavin-1 knockdown. 
This calls into question whether the importance lies in the formation of caveolae 
complex, or expression of each individual protein. Both are reasonable options 
as loss of either protein will cause a collapse of the caveolae structure as well as 
degrade the partner protein. A third option is that both are necessary. The 
structure may be important for proper cellular localization and subsequent 
function of the proteins. Also, the many proposed roles for caveolae and the 
proteins create the possibility that some functions like mechanosensation at the 
membrane rely on the structure while others like signaling are due to different 
protein interaction in the cell. Ultimately, while the question is interesting from a 
scientific standpoint, clinically it may not be relevant. If caveolae or the proteins 
were targeted at a clinical level a structural collapse of caveolae and loss of the 
protein components would take place leading to the same result with both. 
Some clues are present in the caveolin-1 and -2 knockout mice that 
suggest the changes I observed are due to the individual protein expi;"ession and 
not the caveolae structure. In the caveolin~ 1 knockout there is a complete 
morphological loss of caveolae while they remain in the caveolin-2 knockout. 
There has been little functional data described for the role of caveolin-2 other 
than as a caveolin-1 partner, suggesting it is more thought of as an accessory 
protein but because the knockout mouse has normal caveolin-1levels and a lung 
phenotype, there is at a minimum a tissue specific function. A specific function 
for caveolin-2 that is independent of caveolae formation suggests that there is 
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almost certainly a specific role for each protein in the caveolae complex. This 
does not however preclude the possibility that there is also a specific role of the 
caveolae complex and more research is necessary to resolve this issue. 
4.4. Cholesterol Depletion 
Our work supports previous research in that cholesterol is necessary for 
proper caveolae formation. Statin treatment results in a depletion of cholesterol 
from the cell that leads to an immediate collapse of caveolae when cholesterol 
reaches roughly 50% of normal. I see the same results as well as a loss of 
caveolin and cavin proteins. Statin treatment in patients certainly reduces the 
risk of cardiovascular complications but has been suggested by retrospective 
analyses to reduce the risk of developing cancer (Nielsen 2012). Meta analysis 
and epidemiological studies however have not been able to show a direct 
connection in patients currently taking undergoing statin treatment (Dale 2006) . 
Many of these studies though are flawed in that they do not take dosing into 
account as well as do not differentiate between the statins. The dosing necessary 
to lower systemic cholesterol may likely not be the same dose that is needed to 
have an effect on cancer progression. Another large problem is in the lack of 
differentiation between statins because clinically approved drugs differ on their 
lipophilicity. Statins that are targeted to the liver would treat systemic . 
cholesterol levels but would not directly modulate cholesterol levels in tissues 
like the breast. Further analysis and potentially a clinical trial is warranted to 
fully explore statins possible role in cancer. If there is an effect of statiJ;ls, our 
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data suggest that is unlikely to be due to caveolae. First, in breast cancer, 
caveolin-1 and cavin-1 act as tumor suppressors. Cholesterol depletion leads to a 
loss of these proteins that should increase tumorigenesis though in vitro statin 
treatment reduces invasiveness of cancer cells. Secondly, during cholesterol 
depletion~ the loss of caveolae does not take place in a gradient or dose 
dependant way but rather immediately once the cholesterol levels reach a certain 
point. Evidence suggests that while statins may prove to one day be a valuable 
resource in the fight against cancer, it is not because of the disruption of 
caveolae. 
4.5. Clinical Relevance 
Our research into caveolae and the protein constituents suggest that they 
can play a very important clinical role in the near future. First, while our data is 
preliminary on the topic, it suggests that cholesterol depletion through statin 
treatment may have an effect on tumor progression although mechanistically 
may it may have nothing to do with caveolae. Secondly, our data help progress 
understanding of breast cancer. Eventual clinical research arises from 
observations at the level of basic science. By understanding more about 
oncogenes and tumor suppressors as well the molecular biology of breast cancer 
we come one step closer towards clinical advancement. Even if the caveolins and 
cavins do not prove to be effective targets for treatment, our understanding of 
their role in cancer pathology may contribute to personalized medicine. Every 
patient's cancer, while they share similar traits, is ultimately unique. If we know 
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more about what is takjng place in the tumor, we can have a better idea on how 
the tumor will progress and what the best treatment methodology is. 
4.6. Future Directions 
The current understanding of caveolae is not represented in the majority 
of recent publications. The previous paradigm that caveolin-1 is necessary and 
sufficient for caveolae formation is outdated and reliance on it hinders research 
by not acknowledging the other components of caveolae. In order to understand 
how caveolae function, in particular in the context of cancer where data has been 
somewhat convoluted, both caveolin and cavin must be examined. Also, 
research into the dynamics of caveolae and determining the importance between 
individual proteins function, cellular localization, and the formation of caveolae 
will go a long way into shining light on the dichotomy of caveolin-1 in cancer. 
Our data on statin treatment in cancer is minimal and should be looked 
into further. With the low cost and minimal risk associated with statin 
treatment, the possibility that it could play any kind of part in cancer treatment 
needs to be explored. 
When research into caveolin-1 is examined from a broad sense, it 
functions as both an oncogene and tumor suppressor in different tissues and 
stages of cancer. Our data is relatively narrow in that it focuses mostly on ER 
negative breast cancer. In order to better explore the dichotomy of tumor 
suppressor versus oncogene, I need to expand the cell lines. In the ER positive 
cell lines, introducing caveolin-1 and cavin-1 individually and together will 
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allow us to monitor changes in cellular behavior and possibly differentiate 
between the individual proteins and the caveolae structure. Looking at ER 
positive lines will also allow the clinically relevant receptors, ER, PR, and HER2, 
to be examined, something that is not possible in the triple negative MDA-MB-
231 and HS578t cell lines. It will also be important to look beyond breast cancer 
into other tissues. Currently only a handful of papers in breast, prostate, and 
lung exist. Just as other cell lines and tissue should be examined, so should the 
rest of the cavin family. The different gene loci, our Oncomine date, and the 
necessity for cavin-2 for caveolae formation all suggest that they may have a 
functional role in tumorigenesis. Altogether this field is uncharted territory that 
will only prove to be interesting as more is understood. 
105 
List of Journal Abbreviations 
Acta Neuropatho. 
Adv. Exp. Med. Biol. 
Am. J. Med. Genet. 
Am. J. Pathol 
Am. J. Physiol. Cell. Physiol. 
Am. J. Physiol. Heart. Circ. Physiol. 
AnnOncol 
Annu. Rev. Cell Dev. Biol 
Annu. Rev. Pharmacal. Toxicol. 
Toxicology 
Anticancer Res. 
Biochim. Biophys. Acta 
Biochem. Biophys. Res. Commun. 
Biochem. J 
BJUint 
Breast Cancer Res. Treat. 
Acta N europathologica 
Advances in Experimental Medicine 
and Biology 
American Journal of Medical Genetics 
American Journal of Pathology, 
American J oumal of Physiology: Cell 
Physiology 
American J oumal of Physiology: Heart 
and Circulatory Physiology 
Annals of Oncology 
Annual Review of Cell and 
Developmental Biology 
Annual Review of Pharmacology and 
Anticancer Research 
Biochimica et Biophysica Acta 
Biochemical and Biophysical Research 
Communications 
Biochemical Journal 
British Journal of Urology International 
Breast Cancer Research and Treatment 
106 
Br. J. Cancer. British Journal of Cancer 
Cancer Lett. Cancer Letters 
Cancer Res. Cancer Research 
Cell Growth Differ Cell Growth & Differentiation 
Cell Metab Cell Metabolism 
Cell Tissue Res. Cell and Tissue Research 
• 
Clin. Cancer Res. Clinical Cancer Research 
ClinExpMed Clinical and Experimental Medicine 
Clin. Exp. Metastasis. Clinical and Experimental Metastasis 
EMBOJ. European Molecular Biology 
Organization Journal 
Eur J Cell Biol. European Journal of Cell Biology 
Eur. J. Med. Genet. European Journal of Medical Genetics 
FEBS Lett. Federation of European Biochemical 
Societies Letters 
Future Oncol Future Oncology 
Gynecol. Oncol. Gynecologic Oncology 
Hum. Mol. Genet. Human Molecular Genetics 
Int. J. Cancer International Journal of Cancer 
JAMA Journal of the American Medical 
Association 
J. Biol. Chern. The Journal of Biological Chemistry 
J Biomol Screen Journal of Biomolecular Screening 
107 
J. Cell. Biochem. 
J. Cell Bioi. 
J. Cell. Sci. 
J. Clin. Endocrinol. Metab. 
J. Clin. Invest. 
J. Histochem. Cytochem. 
J. Lipid Res. 
J. Med. Genet. 
J. Natl. Cancer Inst. 
Mol. Bioi. Cell 
Mol. Cancer Res. 
Mol Cell Bioi 
Mol. Genet. Metab. 
Mol. Med. 
Mol. Endocrinol. 
Nat. Cell Bioi 
Nat. Genet. 
Nat. Rev. Cancer. 
Nat Rev Mol Cell Bioi 
Oncol. Rep. 
Trends Cell Bioi 
Journal of Cellular Biochemistry 
The Journal of Cell Biology 
Journal of Cell Science 
The Journal of Clinical Endocrinology & 
Metabolism 
The Journal of Clinical Investigation 
Journal of Histochemistry & 
Cytochemistry 
The J oumal of Lipid Research 
Journal of Medical Genetics 
Journal of the National Cancer Institute 
Molecular Biology of the Cell 
Molecular Cancer Research 
Molecular and Cellular Biology 
Molecular Genetics and Metabolism 
Molecular Medicine 
Molecular Endocrinology 
Nature Cell Biology 
Nature Genetics 
Nature Reviews Cancer 
Nature Reviews Molecular Cell Biology 
Oncology Reports 
Trends in Cell Biology 
108 
Trends Endocrinol. Metab. Trends in Endocrinology & Metabolism 
109 
References 
Adams, J.M., and Cory, S. (print). The Bcl-2 apoptotic switch in cancer 
development and therapy. Oncogene 26, 1324-1337. 
Ahnen, D.J., Axell, L. (2012). Clinical manifestations and diagnosis of familial 
adenomatous polyposis. Uptodate.com. [Online]. Available: 
http: I /www.uptodate.com/ contents/ clinical-manifestations-and-diagnosis-of-
familial-adenomatous-polyposis 
Aldred, M.A., Ginn-Pease, M.E., Morrison, C.D., Popkie, A.P., Gimm, 0., Hoang-
Vu, C., Krause, U., Dralle, H., Jhiang, S.M., Plass, C., et al. (2003). Caveolin-1 and 
caveolin-2,together with three bone morphogenetic protein-related genes, may 
encode novel tumor suppressors down-regulated in sporadic follicular thyroid 
carcinogenesis. Cancer Res. 63, 2864-2871. 
Ali, I.lJ., Lidereau, R., Theillet, C., and Callahan, R. (1987). Reduction to 
homozygosity of genes on chromosome 11 in human breast neoplasia. Science 
238, 185-188. 
American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American 
Cancer Society, 2013. 
Ando, T., Ishiguro, H., Kimura, M., Mitsui, A., Mori, Y., Sugito, N., Tomoda, K., 
Mori, R., Harada, K., Katada, T., et al. (2007). The overexpression of caveolin-1 
and caveolin-2 correlates with a poor prognosis and tumor progression in 
esophageal squamous cell carcinoma. Oneal. Rep. 18, 601-609. 
Aung, C.S., Hill, M.M., Bastiani, M., Parton, R.G., and Parat, M.-0. (2010). PTRF-
cavin-1 expression decreases the migration of PC3 prostate cancer cells: Role of 
matrix metalloprotease 9. Eur J Cell Biol. 
Bai, L., Deng, X., Li, Q., Wang, M., An, W., Deli, A., Gao, Z., Xie, Y., Dai, Y., and 
Cong, Y.-S. (2012). Down-regulation of the cavin family proteins in breast cancer. 
J. Cell. Biochem. 113, 322-328. 
Baltierrez-Hoyos, R., Roa-Espitia, A.L., and Hermmdez-Gonzalez, E.O. (2012). 
The association between CDC42 and caveolin-1 is involved in the regulation of 
capacitation and acrosome reaction of guinea pig and mouse sperm. 
Reproduction 144, 123-134. 
Barresi, V., Cerasoli, S., Paioli, G., Vitarelli, E., Giuffre, G., Guiducci, G., Tuccari, 
G., and Barresi, G. (2006). Caveolin-1 in meningiomas: expression and clinico-
pathological correlations. Acta Neuropathol. 112, 617-626. 
Barrett, J.C., Clayton, D.G., Concannon, P., Akolkar, B., Cooper, J.D., Erlich, H.A., 
Julier, C., Morahan, G., Nerup, J., Nierras, C., et al. (2009). Genome-wide 
110 
association study and meta-analysis find that over 40 loci affect risk of type 1 
diabetes. Nat. Genet. 41, 703-707. 
Bastiani, M., and Parton, R.G. (2010). Caveolae at a glance. J. Cell. Sci.123, 3831-
3836. 
Bastiani, M., Liu, L., Hill, M.M., Jedrychowski, M.P., Nixon, S.J., Lo, H.P., 
Abankwa, D., Luetterforst, R., Fernandez-Rojo, M., Breen, M.R., et al. (2009). 
MURC/ Cavin-4 and cavin family members form tissue-specific caveolar 
complexes. J. Cell Biol185, 1259-1273. 
Bouzahzah, B., Albanese, C., Ahmed, F., Pixley, F., Lisanti, M.P., Segall, J.D., 
Condeelis, J., Joyce, D., Minden, A., Der, C.J., et al. (2001). Rho family GTPases 
regulate mammary epithelium cell growth and metastasis through 
distinguishable pathways. Mol. Med. 7, 816-830. 
Breen, M.R., Camps, M., Carvalho-Simoes, F., Zorzano, A., and Pilch, P.F. (2012). 
Cholesterol depletion in adipocytes causes caveolae collapse concomitant with 
proteosomal degradation of cavin-2 in a switch-like fashion. PLoS ONE 7, 
e34516. 
Briand, N., Le Lay, S., Sessa, W.C., Ferre, P., and Dugail, I. (2011). Distinct roles 
of endothelial and adipocyte caveolin-1 in macrophage infiltration and adipose 
tissue metabolic activity. Diabetes 60, 448-453. 
Bridges, D., Chang, L., Lodhi, I.J., Clark, N.A., and Saltiel, A.R. (2012). TC10 is 
regulated by caveolin in 3T3-L1 adipocytes. PLoS ONE 7, e42451. 
Van Buggenhout, G., Van Ravenswaaij-Arts, C., Me Maas, N., Thoelen, R., 
Vogels, A., Smeets, D., Salden, 1., Matthijs, G., Fryns, J.-P., and Vermeesch, J.R. 
(2005). The del(2)(q32.2q33) deletion syndrome defined by clinical and molecular 
characterization of four patients. Eur J Med Genet 48, 276-289. 
Campbell, L., Gumbleton, M., and Griffiths, D.F.R. (2003). Caveolin-1 
overexpression predicts poor disease-free survival of patients with clinically 
confined renal cell carcinoma. Br. J. Cancer 89, 1909-1913. 
Capozza, F., Combs, T.P., Cohen, A.W., Cho, Y.-R., Park, S.-Y., Schubert, W., 
Williams, T.M., Brasaemle, D.L., Jelicks, L.A., Scherer, P.E., et al. (2005). 
Caveolin-3 knockout mice show increased adiposity and whole body insulin 
resistance, with ligand-induced insulin receptor instability in skeletal muscle. 
Am J Physiol Cell Physiol288, C1317-C1331. 
Carver, L.A., and Schnitzer, J.E. (2003). Caveolae: mining little caves for new 
cancer targets. Nat. Rev. Cancer 3, 571-581. 
Cleveland, D.W., Fischer, S.C., Kirschner, M.W., and Laemmli, U.K. (1977). 
111 
Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis 
by gel electrophoresis. J. Biol. Chern. 252, 1102-1106. 
Cohen, A.W., Park, D.S., Woodman, S.E., Williams, T.M., Chandra, M., Shirani, J., 
Pereira de Souza, A., Kitsis, R.N., Russell, R.G., Weiss, L.M., et al. (2003). 
Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of 
p42 I 44 MAP kinase in cardiac fibroblasts. Am. J. Physiol., Cell Physiol 284, 
C457-474. 
Cooper G.M. 2000. The Cell: A Molecular Approach. Massachusetts. Sinauer 
Associates 
Craene, B.D., and Berx, G. (2013). Regulatory networks defining EMT during 
cancer initiation and progression. Nat Rev Cancer 13, 97-110. 
Dale, K.M., Coleman, C.I., Henyan, N.N., Kluger, J., and White, C.M. (2006). 
Statins and cancer risk: a meta-analysis. JAMA 295, 74-80. 
Davidson, B., Nesland, J.M., Goldberg, I., Kopolovic, J., Gotlieb, W.H., Bryne, M., 
Ben-Baruch, G., Berner, A., and Reich, R. (2001). Caveolin-1 expression in 
advanced-stage ovarian carcinoma--a clinicopathologic study. Gynecol. Oneal. 
81, 166-171 . . 
Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., Menne, J., 
Lindschau, C., Mende, F., Luft, F.C., et al. (2001). Loss of caveolae, vascular 
dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 
293, 2449-2452. 
Dwianingsih, E.K., Takeshima, Y., Itoh, K., Yamauchi, Y., Awano, H., Malueka, 
R.G., Nishida, A., Ota, M., Yagi, M., and Matsuo, M. (2010). A Japanese child 
with asymptomatic elevation of serum creatine kinase shows PTRF-CA VIN 
mutation matching with congenital generalized lipodystrophy type 4. Mol. 
Genet. Metab. 101, 233-237. 
Ellenbroek, S.I.J., and Collard, J.G. (2007). Rho GTPases: functions and 
association with cancer. Clin. Exp. Metastasis 24, 657-672. 
Engelman, J.A., Wykoff, C.C., Yasuhara, S., Song, K.S., Okamoto, T., and Lisanti, 
M.P. (1997). Recombinant expression of caveolin-1 in oncogenically transformed 
cells abrogates anchorage-independent growth. J. Biol. Chern 272, 16374-16381. 
Fiucci, G., Ravid, D., Reich, R., and Liscovitch, M. (2002). Caveolin-1 inhibits 
anchorage-independent growth, anoikis and invasiveness in MCF-7 human 
breast cancer cells. Oncogene 21, 2365-2375. 
Frank, P.G., Cheung, M.W.-C., Pavlides, S., Llaverias, G., Park, D.S., and Lisanti, 
M.P. (2006). Caveolin-1 and regulation of cellular cholesterol homeostasis. AmJ 
112 
Physiol Heart Circ Physiol291, H677-H686. 
Fritz, G., Brachetti, C., Bahlmann, F., Schmidt, M., and Kaina, B. (2002). Rho 
GTPases in human breast tumours: expression and mutation analyses and 
correlation with clinical parameters. Br. J. Cancer 87, 635-644. 
Galbiati, F., Volonte, D., Engelman, J.A., Watanabe, G., Burk, R., Pestell, R.G., and 
Lisanti, M.P. (1998). Targeted downregulation of caveolin-1 is sufficient to drive 
cell transformation and hyperactivate the p42/ 44 MAP kinase cascade. EMBO J. 
17, 6633-6648. 
Garg, A., and Agarwal, A.K. (2009). Lipodystrophies: disorders of adipose tissue 
biology. Biochim. Biophys. Acta 1791, 507-513. 
Gingras, D., Gauthier, F., Lamy, S., Desrosiers, R.R., and Beliveau, R. (1998). 
Localization of RhoA GTPase to endothelial caveolae-enriched membrane 
domains. Biochem. Biophys. Res. Commun. 247, 888-893. 
Glass, LA., Swindlehurst, C.A., Aitken, D.A., McCrea, W., and Boyd, E. (1989). 
Interstitial deletion of the long arm of chromosome 2 with normal levels of 
isocitrate dehydrogenase. J. Med. Genet. 26, 127-130. 
Clenney, J.R., and Zokas, L. (1989). Novel tyrosine kinase substrates from Rous 
sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 
108, 2401-2408. 
Gould, M.L., Williams, G., and Nicholson, H.D. (2010). Changes in caveolae, 
caveolin, and polymerase 1 and transcript release factor (PTRF) expression in 
prostate cancer progression. Prostate 70, 1609-1621. 
Gustincich, S., and Schneider, C. (1993). Serum deprivation response gene is 
induced by serum starvation but not by contact inhibition. Cell Growth Differ 4, 
753-760. 
Hailstones, D., Sleer, L.S., Parton, R.G., and Stanley, K.K. (1998). Regulation of 
caveolin and caveolae by cholesterol in MDCK cells. J. Lipid Res 39, 369-379. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell100, 57-
70. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next 
generation. Cell144, 646-67 4. 
Hansen, C.G., and Nichols, B.J. (2010). Exploring the caves: cavins, caveolins and 
• caveolae. Trends Cell Biol20, 177-186. 
Hansen, C.G., Bright, N.A., Howard, G., and Nichols, B.J. (2009). SDPR induces 
113 
membrane curvature and functions in the formation of caveolae. Nat. Cell Bioi 
11, 807-814. 
Hasegawa, T., Takeuchi, A., Miyaishi, 0., Xiao, H., Mao, J., and Isobe, K. (2000). 
PTRF (polymerase I and transcript-release factor) is tissue-specific and interacts 
with the BFCOL1 (binding factor of a type-I collagen promoter) zinc-finger 
transcription factor which binds to the two mouse type-I collagen gene 
promoters. Biochem. J 347 Pt 1, 55-59. 
Hayashi, Y.K., Matsuda, C., Ogawa, M., Goto, K., Tominaga, K., Mitsuhashi, S., 
Park, Y.-E., Nonaka, 1., Hino-Fukuyo, N., Haginoya, K., et al. (2009). Human 
PTRF mutations cause secondary deficiency of caveolins resulting in muscular 
dystrophy with generalized lipodystrophy. J. Clin. Invest. 119, 2623-2633. 
Haynes, J., Srivastava, J., Madson, N., Wittmann, T., and Barber, D.L. (2011). 
Dynamic actin remodeling during epithelial-mesenchymal transition depends on 
increased moesin expression. Mol. Bioi. Cell22, 4750-4764. 
Van Hengel, J., D'Hooge, P., Hooghe, B., Wu, X., Libbrecht, L., DeVos, R., 
Quondamatteo, F., Klempt, M., Brakebusch, C., and Van Roy, F. (2008). 
Continuous cell injury promotes hepatic tumorigenesis in cdc42-deficient mouse 
liver. Gastroenterology 134, 781-792. 
Herrmann, H., Bar, H., Kreplak, L., Strelkov, S.V., and Aebi, U. (2007). 
Intermediate filaments: from cell architecture to nanomechanics. Nat Rev Mol 
Cell Bioi 8, 562-573. 
Hill, M.M., Bastiani, M., Luetterforst, R., Kirkham, M., Kirkham, A., Nixon, S.J., 
Walser, P., Abankwa, D., Oorschot, V.M.J., Martin, S., et al. (2008), PTRF-Cavin, a 
conserved cytoplasmic protein required for caveola formation and function. Cell 
132, 113-124. 
Ho, C.-C., Huang, P.-H., Huang, H.-Y., Chen, Y.-H., Yang, P.-C., and Hsu, S.-M. 
(2002). Up-regulated caveolin-1 accentuates the metastasis capability of lung 
adenocarcinoma by inducing filopodia formation. Am. J. Pathol161, 1647-1656. 
Ho, C.-C., Kuo, S.-H., Huang, P.-H., Huang, H.-Y., Yang, C.-H., and Yang, P.-C. 
(2008). Caveolin-1 expression is significantly associated with drug resistance and 
poor prognosis in advanced non-small cell lung cancer patients treated with 
gemcitabine-based chemotherapy. Lung Cancer 59, 105-110. 
Howard, J., and Hyman, A.A. (2003). Dynamics and mechanics of the 
microtubule plus end. Nature 422, 753-758. 
Howell, A., Osborne, C.K., Morris, C., and Wakeling, A.E. (2000). ICI 182,780 
(Faslodex): development of a novel, "pure" antiestrogen. Cancer 89, 817-825. 
114 
Ikram, M.A., Fornage, M., Smith, A.V., Seshadri, S., Schmidt, R., Debette, S., 
Vrooman, H.A., Sigurdsson, S., Ropele, S., Taal, H.R., et al. (2012). Common 
variants at 6q22 and 17q21 are associated with intracranial volume. Nat. Genet. 
44, 539-544. 
Ikushima, H ., and Miyazono, K. (2010). TGFbeta signalling: a complex web in 
cancer progression. Nat. Rev. Cancer 10, 415-424. 
Izumi, Y., Hirai, S. i, Tarnai, Y., Fujise-Matsuoka, A., Nishimura, Y., and Ohno, S. 
(1997). A protein kinase Cdelta-binding protein SRBC whose expression is 
induced by serum starvation. J. Biol. Chern 272, 7381-7389. 
Jansa, P., Mason, ?.W., Hoffmann-Rohrer, U., and Grummt, I. (1998). Cloning 
and functional characterization of PTRF, a novel protein which induces 
dissociation of paused ternary transcription complexes. EMBO J.17, 2855-2864. 
Jaffe, A.B., and Hall, A. (2005). Rho GTPases: biochemistry and biology. Annu. 
Rev. Cell Dev. Biol. 21, 247-269. 
Jiang, W.G., Watkins, G., Lane, J., Cunnick, G.H., Douglas-Jones, A., Mokbel, K., 
and Mansel, R.E. (2003). Prognostic value of rho GTPases and rho guanine 
nucleotide dissociation inhibitors in human breast cancers. Clin. Cancer Res. 9, 
6432-6440. 
Joo, H.J., Oh, D.K., Kim, Y.S., Lee, K.B., and Kim, S.J. (2004). Increased expression 
of caveolin-1 and microvessel density correlates with metastasis and poor 
prognosis in clear cell renal cell carcinoma. BJU Int 93, 291-296. 
Kakinuma, N., Kohu, K., Sato, M., Yamada, T., Nakajima, M., Akiyama, T., 
Ohwada, S., and Shibanaka, Y. (2004). Candidate regions of tumor suppressor 
locus on chromosome 9q31.1 in gastric cancer. Int. J. Cancer 109, 71-75. 
Karnik, P., Paris, M., Williams, B.R.G., Casey, G., Crowe, J., and Chen, P. (1998). 
Two Distinct Tumor Suppressor Loci Within Chromosome llp15 Implicated in 
Breast Cancer Progression and Metastasis. Hum. Mol. Genet. 7, 895-903. 
Kato, H., Yoshikawa, M., Miyazaki, T., Nakajima, M., Fukai, Y., Masuda, N., 
Fukuchi, M., Manda, R., Tsukada, K., and Kuwano, H. (2002). Expression of 
vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in 
esophageal squamous cell carcinoma. Anticancer Res. 22, 3977-3984. 
Kibbey, M.C. (1994). Maintenance of the EHS sarcoma and Matrigel preparation. 
Journal of Tissue Culture Methods 16, 227-230. 
Kim, C.A., Delepine, M., Boutet, E., El Mourabit, H., Le Lay, S., Meier, M., 
Nemani, M., Bridel, E., Leite, C.C., Bertola, D.R., et al. (2008). Association of a 
homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital 
115 
lipodystrophy. J. Clin. Endocrinol. Metab. 93, 1129-1134. 
Kim, J.H., Dhanasekaran, S.M., Mehra, R., Tomlins, S.A., Gu, W., Yu, J., Kumar-
Sinha, C., Cao, X., Dash, A., Wang, L., et al. (2007). Integrative analysis of 
genomic aberrations associated with prostate cancer progression. Cancer Res. 67, 
8229-8239. 
Kiss, A.L. (2012). Caveolae and the regulation of endocytosis. Adv. Exp. Med. 
Biol. 729, 14-28. 
Koleske, A.J., Baltimore, D., and Lisanti, M.P. (1995). Reduction of caveolin and 
caveolae in oncogenically transformed cells. Proc. Natl. Acad. Sci. U.S.A 92, 
1381-1385. 
Kurzchalia, T.V., Dupree, P., Parton, R.G., Kellner, R., Virta, H., Lehnert, M., and 
Simons, K. (1992). VIP21, a 21-kD membrane protein is an integral component of 
trans-Golgi-network-derived transport vesicles. J. Cell Biol. 118, 1003-1014. 
Lee, S.W., Reimer, C.L., Oh, P., Campbell, D.B., and Schnitzer, J.E. (1998). Tumor 
cell growth inhibition by caveolin re-expression in human breast cancer cells. 
Oncogene 16, 1391-1397. 
Levin, E.R. (2009). Plasma membrane estrogen receptors. Trends Endocrinol. 
Metab. 20,477-482. 
Levin, E.R. (2010). Minireview: Extranuclear Steroid Receptors: Roles in 
Modulation of Cell Functions. Mol. Endocrinol. 
Li, L., Ren, C., Yang, G., Goltsov, A.A., Tabata, K., and Thompson, T.C. (2009). 
Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-
promoting growth factors in prostate cancer cells. Mol. Cancer Res. 7, 1781-1791. 
Li, S., Han, B., Liu, G., Li, S., Ouellet, J., Labrie, F., and Pelletier, G. (2010). 
Immunocytochemical localization of sex steroid hormone receptors in normal 
human mammary gland. J. Histochem. Cytochem. 58, 509-515. 
Li, T., Sotgia, F., V-qolo, M.A., Li, M., Yang, W.C., Pestell, R.G., Sparano, J.A., and 
Lisanti, M.P. (2006). Caveolin-1 mutations in human breast cancer: functional 
association with estrogen receptor alpha-positive status. Am. J. Pathol168, 1998-
2013. 
Lingwood, D., and Simons, K. (2010). Lipid Rafts As a Membrane-Organizing 
Principle. Science 327, 46-50. 
Liu, L., Brown, D., McKee, M., Lebrasseur, N.K., Yang, D., Albrecht, K.H., Ravid, 
K., and Pilch, P.F. (2008). Deletion of Cavin/PTRF causes global loss of caveolae, 
dyslipidemia, and glucose intolerance. Cell Metab 8, 310-317. 
116 
Lowe, S.W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression. 
Nature 432, 307-315. 
Magre, J., Delepine, M., Khallouf, E., Gedde-Dahl, T., Jr, Van Maldergem, L., 
Sobel, E., Papp, J., Meier, M., Megarbane, A., Bachy, A., et al. (2001). 
Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy 
on chromosome llq13. Nat. Genet. 28,365-370. 
Van Maldergem, L. (1993). Berardinelli-Seip Congenital Lipodystrophy. In 
GeneReviews™, R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens, and M.P. Adam, 
eds. (Seattle (WA): University of Washington, Seattle),. 
McMahon, K.-A., Zajicek, H ., Li, W.-P., Peyton, M.J., Minna, J.D., Hernandez, 
V.J., Luby-Phelps, K., and Anderson, R.G.W. (2009). SRBC/ cavin-3 is a caveolin 
adapter protein that regulates caveolae function. EMBO J 28, 1001-1015. 
Meshulam, T., Simard, J.R., Wharton, J., Hamilton, J.A., and Pilch, P.F. (2006). 
Role of caveolin-1 and cholesterol in transmembrane fatty acid movement. 
Biochemistry 45, 2882-2893. 
Miller, F.R., Santner, S.J., Tait, L., and Dawson, P.J. (2000). MCF10DCIS.com 
xenograft model of human comedo ductal carcinoma in situ. J. Natl. Cancer Inst. 
92, 1185-1186. 
Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti, E., 
Mazzocco, M., Egeo, A., Donati, M.A., et al. (1998). Mutations in the caveolin-3 
gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18, 
365-368. 
Moon, K.C., Lee, G.K., Yoo, S.-H., Jeon, Y.K., Chung, J.-H., Han, J., and Chung, 
D.H. (2005). Expression of caveolin-1 in pleomorphic carcinoma of the lung is 
correlated with a poor prognosis. Anticancer Res. 25, 4631-4637. 
Mundy, D.I., Machleidt, T., Ying, Y., Anderson, R.G.W., and Bloom, G.S. (2002). 
Dual control of caveolar membrane traffic by microtubules and the actin 
cytoskeleton. J. Cell. Sci. 115, 4327-4339. 
Munoz, R., Man, S., Shaked, Y., Lee, C.R., Wong, J., Francia, G., and Kerbel, R.S. 
(2006). Highly efficacious nontoxic preclinical treatment for advanced metastatic 
breast cancer using combination oral UFT -cyclophosphamide metronomic 
chemotherapy. Cancer Res. 66,3386-3391. 
Nassoy, P., and Lamaze, C. (2012). Stressing caveolae new role in cell mechanics. 
Trends Cell Biol. 22, 381-389. 
Neklason, D.W., Kerber, R.A., Nilson, D.B., Anton-Culver, H., Schwartz, A.G., 
Griffin, C.A., Lowery, J.T., Schildkraut, J.M., Evans, J.P., Tomlinson, G.E., et al. 
117 
(2008). Common familial colorectal cancer linked to chromosome 7q31: a 
genome-wide analysis. Cancer Res. 68, 8993-8997. 
Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., 
Bayani, N., Coppe, J.-P., Tong, F., et al. (2006). A collection of breast cancer cell 
lines for the study of functionally distinct cancer subtypes. Cancer Cell10, 515-
527. 
Nevins, A.K., and Thurmond, D.C. (2006). Caveolin-1 functions as a novel Cdc42 
guanine nucleotide dissociation inhibitor in pancreatic beta-cells. J. Bioi. Chern. 
281, 18961-18972. 
Nielsen, S.F., Nordestgaard, B.G., and Bojesen, S.E. (2012). Statin Use and 
Reduced Cancer-Related Mortality. New England Journal of Medicine 367, 1792-
1802. 
Norica Branza-Nichita, Alina Macovei and Catalin Lazar (2012). Caveolae-
Dependent Endocytosis in Viral Infection, Molecular Regulation of Endocytosis, 
Dr. Brian Ceresa (Ed.), ISBN: 978-953:..51-0662-3, InTech, DOl: 10.5772/48538. 
Available from: http: I I www.intechopen.com /books I molecular-regulation-of-
endocytosis I caveolae-dependent-endocytosis-in-viral-infection 
Palade, G. E. (1953). Fine Structure of Blood Capillaries. J. Appl. Phys. 24, 1424-
1436. 
Pardali, K., and Moustakas, A. (2007). Actions of TGF-beta as tumor suppressor 
and pro-metastatic factor in human cancer. Biochim. Biophys. Acta 1775, 21-62. 
Parolini, 1., Sargiacomo, M., Galbiati, F., Rizzo, G., Grignani, F., Engelman, J.A., 
Okamoto, T., lkezu, T., Scherer, P.E., Mora, R., et al. (1999). Expression of 
caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. 
Retention of caveolin-2 at the level of the golgi complex. J. Bioi. Chern. 274, 
25718-25725. 
Park, D.S., Woodman, S.E., Schubert, W., Cohen, A.W., Frank, P.G., Chandra, M., 
Shirani, J., Razani, B., Tang, B., Jelicks, L.A., et al. (2002). Caveolin-1/3 double-
knockout mice are viable, but lack both muscle and non-muscle caveolae, and 
develop a severe cardiomyopathic phenotype. Am. J. Pathol. 160,2207-2217. 
Park, D.S., Cohen, A.W., Frank, P.G., Razani, B., Lee, H., Williams, T.M., 
Chandra, M., Shirani, J., De Souza, A.P., Tang, B., et al. (2003). Caveolin-1 null(-
/-)mice show dramatic reductions in life span. Biochemistry 42, 15124-15131. 
Parton, R.G., and Simons, K. (2007). The multiple faces of caveolae. Nat. Rev. 
Mol. Cell Biol8, 185-194. 
Patel, H.H., Murray, F., and Insel, P.A. (2008). Caveolae as organizers of 
118 
pharmacologically relevant signal transduction molecules. Annu. Rev. 
Pharmacal. Toxicol. 48, 359-391. 
Pelkmans, L., and Zerial, M. (2005). Kinase-regulated quantal assemblies and 
kiss-and-run recycling of caveolae. Nature 436, 128-133. 
Pike, L.J. (2003). Lipid rafts bringing order to chaos. J. Lipid Res. 44, 655-667. 
Radhakrishnan, A., Goldstein, J.L., McDonald, J.G., and Brown, M.S. (2008). 
Switch-like control of SREBP-2 transport triggered by small changes in ER 
cholesterol: a delicate balance. Cell Metab. 8, 512-521. 
Rao, X., Evans, J., Chae, H., Pilrose, J., Kim, S., Yan, P., Huang, R.-L., Lai, H.-C., 
Lin, H., Liu, Y., et al. (2012). CpG island shore methylation regulates caveolin-1 
expression in breast cancer. Oncogene. 
Razani, B., Altschuler, Y., Zhu, L., Pestell, R.G., Mostov, K.E., and Lisanti, M.P. 
(2000). Caveolin-1 expression is down-regulated in cells transformed by the 
human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 
expression suppresses HPV-mediated cell transformation. Biochemistry 39, 
13916-13924. 
Razani, B., Engelman, J.A., Wang, X.B., Schubert, W., Zhang, X.L., Marks, C.B., 
Macaluso, F., Russell, R.G., Li, M., Pestell, R.G., et al. (2001). Caveolin-1 Null 
Mice Are Viable but Show Evidence of Hyperproliferative and Vascular 
Abnormalities. J. Biol. Chern. 276, 38121-38138. 
Razani, B., Combs, T.P., Wang, X.B., Frank, P.G., Park, D.S., Russell, R.G., Li, M., 
Tang, B., Jelicks, L.A., Scherer, P.E., et al. (2002a). Caveolin-1-deficient mice are 
lean, resistant to diet-induced obesity, and show hypertriglyceridemia with 
adipocyte abnormalities. J. Biol. Chern 277, 8635-8647. 
Razani, B., Wang, X.B., Engelman, J.A., Battista, M., Lagaud, G., Zhang, X.L., 
Kneitz, B., Hou, H., Christ, G.J., Edelmann, W., et al. (2002b). Caveolin-2-
Deficient Mice Show Evidence of Severe Pulmonary Dysfunction without 
Disruption of Caveolae. Mol Cell Biol22, 2329-2344. 
Reeves, V.L., Thomas, C.M., and Smart, E.J. (2012). Lipid rafts, caveolae and GPI-
linked proteins. Adv. Exp. Med. Biol. 729, 3-13. 
Roberts, A., Nancarrow, D., Clendenning, M., Buchanan, D.D., Jenkins, M.A., 
Duggan, D., Taverna, D., McKeone, D., Walters, R., Walsh, M.D., et al. (2011). 
Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass 
syndrome). Fam. Cancer 10, 245-254. 
Sagara, Y., Mimori, K., Yoshinaga, K., Tanaka, F., Nishida, K., Ohno, S., Inoue, 
H., and Mori, M. (2004). Clinical significance of Caveolin-1, Caveolin-2 and 
119 
HER2Ineu mRNA expression in human breast cancer. Br. J. Cancer 91, 959-965. 
Sahai, E., and Marshall, C.J. (2002). RHO-GTPases and cancer. Nat. Rev. Cancer 
2, 133-142. 
Sareeboot, T., Punyarit, P., and Petmitr, S. (2011). DNA amplification on 
chromosome 13q31.1 correlated with poor prognosis in colorectal cancer. Clin 
Exp Med 11,97-103. 
Savage, K., Lambros, M.B.K., Robertson, D., Jones, R.L., Jones, C., Mackay, A., 
James, M., Hornick, J.L., Pereira, E.M., Milanezi, F., et al. (2007). Caveolin 1 is 
overexpressed and amplified in a subset of basal-like and metaplastic breast 
carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ 
hybridization analysis. Clin. Cancer Res 13, 90-101. 
Savage, K., Leung, S., Todd, S.K., Brown, L.A., Jones, R.L., Robertson, D., James, 
M., Parry, S., Rodrigues Pinilla, S.M., Huntsman, D., et al. (2008). Distribution 
and significance of caveolin 2 expression in normal breast and invasive breast 
cancer: an immunofluorescence and immunohistochemical analysis. Breast 
Cancer Res. Treat. 110, 245-256. 
Savagner, P. (2010). The epithelial-mesenchymal transition (EMT) phenomenon. 
Ann Oncol 21, vii89-vii92. 
Schiaffino, S. (2012). Tubular aggregates in skeletal muscle: Just a special type of 
protein aggregates? Neuromuscular Disorders 22, 199-207. 
Schubert, W., Sotgia, F., Cohen, A.W., Capozza, F., Bonuccelli, G., Bruno, C., 
Minetti, C., Bonilla, E., DiMauro, S., and Lisanti, M.P. (2007). Caveolin-1(- I-)-
and Caveolin-2(-I-)-Deficient Mice Both Display Numerous Skeletal Muscle 
Abnormalities, with Tubular Aggregate Formation. Am J Pathol170, 316-333. 
Serra, M., and Scotlandi, K. (2009). Caveolins in the development and diseases of 
musculoskeletal system. Cancer Lett. 284, 113-121. 
Shankar, J., Messenberg, A., Chan, J., Underhill, T.M., Foster, L.J., and Nabi, I.R. 
(2010). Pseudopodia! Actin Dynamics Control Epithelial-Mesenchymal 
Transition in Metastatic Cancer Cells. Cancer Res 70, 3780-3790. 
Shastry, S., Delgado, M.R., Dirik, E., Turkmen, M., Agarwal, A.K., and Garg, A. 
(2010). Congenital generalized lipodystrophy, type 4 (CGL4) associated with 
myopathy due to novel PTRF mutations. Am. J. Med. Genet. A 152A, 2245-2253. 
Simard, J.R., Meshulam, T., Pillai, B.K., Kirber, M.T., Brunaldi, K., Xu, S., Pilch, 
P.F., and Hamilton, J.A. (2010). Caveolins sequester FA on the cytoplasmic leaflet 
of the plasma membrane, augment triglyceride formation, and protect cells from 
lipotoxicity. J. Lipid Res. 51, 914-922. 
120 
Shi, F., Sottile, J. (2008). Caveolin-1-dependent beta1 integrin endocytosis is a 
critical regulator of fibronectin turnover. J. Cell Sci. 121, 2360-2371. 
Singer, S.J., and Nicolson, G.L. (1972). The fluid mosaic model of the structure of 
cell membranes. Science 175, 720-731. 
Sinha, B., Koster, D., Ruez, R., Gonnord, P., Bastiani, M., Abankwa, D., Stan, R.V., 
Butler-Browne, G., Vedie, B., Johannes, L., et al. (2011). Cells Respond to 
Mechanical Stress by Rapid Disassembly of Caveolae. Cell144, 402-413. 
Stahlhut, M., van Deurs, B. (2000). Identification of filamin as a novel ligand for 
caveolin-1: Evidence for the organization of caveolin-1-associated membrane 
domains by the actin cytoskeleton. Mol. Bio. Cell. 11, 325-337. 
Sunaga, N., Miyajima, K., Suzuki, M., Sato, M., White, M.A., Ramirez, R.D., Shay, 
J.W., Gazdar, A.F., and Minna, J.D. (2004). Different roles for caveolin-1 in the 
development of non-small cell lung cancer versus small cell lung cancer. Cancer 
Res. 64,4277-4285. 
Surviladze, Z., Waller, A., Wu, Y., Romero, E., Edwards, B.S., Wandinger-Ness, 
A., and Sklar, L.A. (2010). Identification of a small GTPase inhibitor using a high-
throughput flow cytometry bead-based multiplex assay. J Biomol Screen 15, 10-
20. 
Suzuoki, M., Miyamoto, M., Kato, K., Hiraoka, K., Oshikiri, T., Nakakubo, Y., 
Fukunaga, A., Shichinohe, T., Shinohara, T., Itoh, T., et al. (2002). Impact of 
caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J 
Cancer 87, 1140-1144. 
Thorn, H., Stenkula, KG., Karlsson, M., Ortegren, U., Nystrom, F.H., 
Gustavsson, J., and Stralfors, P. (2003). Cell Surface Orifices of Caveolae and 
Localization of Caveolin to the Necks of Caveolae in Adipocytes. Mol. Biol. Cell 
14, 3967-3976. 
Van Etten, R.A. (2013). Cellular and molecular biology of chronic myeloid 
leukemia. Uptodate.com. [Online]. Available: 
http: I I www. uptodate.com I contents I cellular-and-molecular-biology-of-
chronic-myeloid-
leukemia ?source=search_result&search=chronic+myelogenous+ leukemia&select 
edTitle=5~ 150 
Vega, F.M., and Ridley, A.J. (2008). Rho GTPases in cancer cell biology. FEBS 
Lett. 582, 2093-2101. 
Vinten, J., Voldstedlund, M.,_ Clausen, H., Christiansen, K., Carlsen, J., and 
Tranum-Jensen, J. (2001). A 60-kDa protein abundant in adipocyte caveolae. Cell 
Tissue Res. 305, 99-106. 
121 
Vinten, J., Johnsen, A.H., Roepstorff, P., Harp0th, J., and Tranum-Jensen, J. 
(2005). Identification of a major protein on the cytosolic face of caveolae. Biochim. 
Biophys. Acta 1717, 34-40. 
Wiechen, K., Sers, C., Agoulnik, A., Arlt, K., Dietel, M., Schlag, P.M., and 
Schneider, U. (2001). Down-regulation of caveolin-1, a candidate tumor 
suppressor gene, in sarcomas. Am. J. Pathol. 158, 833-839. 
Wikman, H., Seppanen, J.K., Sarhadi, V.K., Kettunen, E., Salmenkivi, K., Kuosma, 
E., Vainio-Siukola, K., Nagy, B., Karjalainen, A., Sioris, T., et al. (2004). Caveolins 
as tumour markers in lung cancer detected by combined use of eDNA and tissue 
microarrays. J. Pathol. 203, 584-593. 
Wikman, H., Sielaff-Frimpong, B., Kropidlowski, J., Witzel, 1., Milde-Langosch, 
K., Sauter, G., Westphal, M., Lamszus, K., and Pantel, K. (2012). Clinical 
Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association 
with Loss of PRKCDBP Expression in Brain Metastases. PLoS ONE 7, e47537. 
Williams, T.M., Cheung, M.W.-C., Park, D.S., Razani, B., Cohen, A.W., Muller, 
W.J., Di Vizio, D., Chopra, N.G., Pestell, R.G., and Lisanti, M.P. (2003). Loss of 
caveolin-1 gene expression accelerates the development of dysplastic mammary 
lesions in tumor-prone transgenic mice. Mol. Biol. Cell14, 1027-1042. 
Williams, T.M., Medina, F., Badano, 1., Hazan, R.B., Hutchinson, J., Muller, W.J., 
Chopra, N.G., Scherer, P.E., Pestell, R.G., and Lisanti, M.P. (2004). Caveolin-1 
gene disruption promotes mammary tumorigenesis and dramatically enhances 
lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix 
metalloproteinase (MMP-2/9) secretion. J. Biol. Chern 279, 51630-51646. 
Winqvist, R., Hampton, G.M., Mannermaa, A., Blanco, G., Alavaikko, M., 
Kiviniemi, H., Taskinen, P.J., Evans, G.A., Wright, F.A., Newsham, I., et al. 
(1995). Loss of Heterozygosity for Chromosome 11 in Primary Human Breast 
Tumors Is Associated with Poor Survival after Metastasis. Cancer Res 55, 2660-
2664. 
Woodman, S.E., Park, D.S., Cohen, A.W., Cheung, M.W.-C., Chandra, M., 
Shirani, J., Tang, B., Jelicks, L.A., Kitsis, R.N., Christ, G.J., et al. (2002). Caveolin-3 
Knock-out Mice Develop a Progressive Cardiomyopathy and Show 
Hyperactivation of the p42/ 44 MAPK Cascade. J. Biol. Chern. 277, 38988-38997. 
Wu, P., Wang, X., Li, F., Qi, B., Zhu, H., Liu, S., Cui, Y., and Chen, J. (2008). 
Growth suppression of MCF-7 cancer cell-derived xenografts in nude mice by 
caveolin-1. Biochem. Biophys. Res. Commun 376, 215-220. 
Yang, G., Truong, L.D., Wheeler, T.M., and Thompson, T.C. (1999). Caveolin-1 
expression in clinically confined human prostate cancer: a novel prognostic 
marker. Cancer Res. 59,5719-5723. 
122 
Yang, G., Timme, T.L., Frolov, A., Wheeler, T.M., and Thompson, T.C. (2005). 
Combined c-Myc and caveolin-1 expression in human prostate carcinoma 
predicts prostate carcinoma progression. Cancer 103, 1186-1194. 
Yoo, S.-H., Park, Y.S., Kim, H.-R., Sung, S.W., Kim, J.H., Shim, Y.S., Lee, S.D., 
Choi, Y.-L., Kim, M.-K, and Chung, D.H. (2003). Expression of caveolin-1 is 
associated with poor prognosis of patients with squamous cell carcinoma of the 
lung. Lung Cancer 42, 195-202. 
Zhang, J., Chen, Y.-H., and Lu, Q. (2010). Pro-oncogenic and anti-oncogenic 
pathways: opportunities and challenges of cancer therapy. Future Oncol 6, 587-
603. 
123 
Curriculum Vitae 
Brian Honeyman 
 
Honeyman@bu.edu 
 
Education 
M.D. in progress, Boston University School of Medicine, Boston, MA 
Ph.D. Molecular Medicine in progress, Boston University School of Medicine, 
Boston, MA 
B.A. 2006, Augustana College, Rock Island, IL 
• Major: Biology and Pre-medicine 
• Minor: Biochemistry, Chemistry, and Speech Communication 
Awards 
• Boston University Graduate Student Employee of the Year, 2013 
• Metabolism, Endocrinology and Obesity Training Grant, 2009-2013 
• Travel Award American Society Virology 2009 Conference, 2009 
• Wotiz Family Fellowship, 2nd Year MD /PhD Fellowship, $6,000, 2007 
• Bemsten Award, $250 Undergraduate Research Grant, 2003 
• Geneva Academic Foundation Research Grant, $10,000, 2001 
Publications 
• Honeyman, B. (2005). Stability study of self-assembled monolayers on 
silicon(lll). Nanoscape, 2, 89-95 
• Honeyman, B., Spalding, C., Jensen, D. (2005). Tautomerism and 1H and 
13C NMR assignments of methyl derivatives of 9-hydroxyphenalenone. 
Magnetic Resonance in Chemistry, 43, 1053-105 
• Filone CM, Hodges EN, Honeyman B, Bushkin GG, Boyd K, Platt A, Ni F, 
Strom K, Hensley L, Snyder JK, Connor JH. (2013). Identification of a 
broad-spectrum inhibitor of viral RNA synthesis: validation of a prototype 
virus-based approach. Chemistry and Biology. 20(3), 424-33. 
Research Experience 
Graduate Student, Pilch Lab, Department Molecular Medicine, BUSM, 2009-
Present 
124 
Graduate Student, Connor Lab, Deparment Microbiology, BUSM, 2008-2009 
Undergraduate Researcher, Kline lab, University Iowa, summer 2005 
Undergraduate Researcher, Bedzyk lab, Northwestern University, summer 2004 
Undergraduate Researcher, Jensen lab, Chemistry, Augustana College, 2004-2006 
Undergraduate Researcher, Lori Scott, Augustana College, 2002-2003 
Poster and Presentations 
BU Recruitment Day, Poster, 2012 
BSO Student Research Day, Poster, 2012 
National MD /PhD Conference, Poster, 2007, 2009, and 2010 . 
Sigma Xi National Conference, Poster, 2006 
University of Iowa Undergraduate Scientific Poster Competition, Poster, 2006 
Teaching Experience 
Tutor, BUSM, 2008-2013 
Teaching Assistant, Medical Microbiology Laboratory, BUSM, 2008-2012 
Lecturer, New England College of Optometry, Boston, 2009 
Teaching Assistant, Cell Biology, Augustana College, 2003-2004 
Tutor, Department of Chemistry, Augsutana College, 2003-2005 
Activities and Organizations 
Augustana Policy Debate Team 
• Academic All American 2005 and 2006 
Phi Beta Kappa 
Sigma Xi, national research society, 2004-2006 
Beta Beta Beta, national biological honors society, 2004-2006 
Augustana Cross Country and Track 
Logos, Augustana honors program, 2003-2006 
Aristeria, Augustana freshman honors society 
125 
